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Abstract 
The lack of treatment facilities and services for opioid use disorder in Maine, combined with an 
increased prevalence of addiction, creates a potential for health inequity between men and women 
that may be intensified by barriers in access to care.  This capstone study utilized detoxification 
screening inquiry forms and data obtained from the Milestone Foundation’s acute opioid 
detoxification program to assess and categorize barriers to access by gender.  A barriers model 
was developed based on existing literature and was to identify potential associations among and 
between the known barriers to accessing treatment.  Barriers were described as internally or 
externally based, and categorized as pertaining to availability, affordability, accommodation, 
accessibility, and acceptability.  Categories were compartmentalized in the barrier model by using 
a framework of structure, process, and outcome, which are Avedis Donabedien’s triad of 
healthcare quality.  The results of the study demonstrate that the Milestone Foundation acute opioid 
detoxification program anticipates and mitigates many of the potential barriers to women, by 
counteracting deficiencies of specific components in the barrier model with strengths from other 
components in the category, or with linked components in an associated category.  Barriers that 
prevent women from requesting treatment may still present a problem.  Further revisions may be 
necessary as the prevalence of opioid use disorder in women continue.   
 Keywords: barriers, access, opioid, detoxification, gender, women, Donabedien 
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Executive Summary 
 The causality of Maine’s current opioid use disorder (OUD) crisis may be linked to the 
high rate of prescribing long-acting and high-dose pain relievers in the state.  Overdoses and deaths 
have increased annually, and women are becoming increasingly affected by OUD.  The limited 
number of treatment facilities and providers as well as the increased request for services may 
potentially cause a health inequity that is disproportionately affecting women. 
 Located in Portland, the Milestone Foundation is Maine’s only non-hospital based acute 
detoxification program, and one of few Maine organizations that will admit people into a 
detoxification program without health insurance.  The purpose of this study was to provide 
Milestone Foundation stakeholders with more information about women’s access to the acute 
opioid detoxification program, using the detoxification inquiry screening forms that were 
completed on each request for treatment.     
  De-identified detoxification inquiry screening forms were analyzed to gather data on 
clients requesting opioid detoxification.  The analysis comprised a review of six months of requests 
for opioid detoxification admission, using the data available on the detoxification inquiry screening 
forms and data obtained from the Milestone Foundation for the months of January, February, June, 
and July of 2015, and January and February of 2016. 
 Data obtained from the detoxification inquiry screening forms were assessed by gender to 
demonstrate potential barriers to access.  Barriers to access were categorized using Penchansky 
and Thomas’ (1981) classifications of availability, affordability, accommodation, accessibility, 
and acceptability.   
 Availability barriers related to treatment non-entry due to filled capacity or gender issues. 
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o This barrier was identified in the study by non-admission due to “PROGRAM 
FULL,” or by LACK OF FEMALE BEDS comments on the detoxification inquiry 
screening forms.   
 Affordability barriers were defined as the individual’s financial situation such as lack of 
insurance prevented access to care.   
o This barrier was identified in the study by INSURANCE STATUS.  
 Accommodation barriers dealt with access related to hours of operation, 
telecommunications, as well as the ability or inability to make modifications to the system.     
o This barrier was identified in the study by TIMES OF CONTACT, and identified 
anecdotally by HOURS OF ADMISSION and PHONE AVAILABILITY.  
Modifications to improve this barrier were identified anecdotally by 
REARRANGING CLIENTS BEDS/WARDS and a NEW SCREENING/CALL 
BACK PROCESS WITH PREGNANT CLIENTS. 
 Accessibility barriers included family care and responsibility, transportation, health issues 
preventing entry, or incarceration.   
o This barrier was identified in the study by non-admission due to NO SHOWS, 
MEDICAL CLEARANCE, or LEGAL/MEDICAL APPOINTMENT, and by 
comments on the detoxification inquiry screening forms. 
 Acceptability barriers covered the internal barriers of shame and stigma, as well as fear of 
consequences and treatment difficulties.   
o This barrier was identified in the study by non-admission due to SELF-REFUSAL, 
and by comments on the detoxification inquiry screening forms. 
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 I identified these 5 barriers as internal or external.  The designation was determined by 
whether they were developed within the individual through actions and beliefs (internal) or caused 
externally by systems or processes in the individual’s surroundings (Hecksher and Hesse, 2009).  
Finally, I grouped the categories using Donabedian’s (1988) framework of healthcare 
quality - structure, process, and outcome.  Structure described the contextual aspect of the system 
and included components such as physical structures, organizational staffing, and insurance 
availability.  Process described the procedures utilized in the system, and the actions taken by all 
involved.  Outcome described effects of the system, and the results of processes (Donabedian, 
1988, 2005).    
I developed a barrier model to demonstrate the synthesis of the three concepts.  The model 
illustrated associations among and between the barriers to access. 
 
An Analysis of Women’s Access to Opioid Detoxification                                         C o n l e y  |5  
 
 
 
 Over the time frame of the study, 356 individuals requested opioid detoxification treatment. 
Phone calls were the mode of contact for 92% of the requests. The clients consisted of 252 men 
and 104 women, resulting in a relative frequency of 2.42 men: 1 woman requesting treatment.  
Men were more likely to be homeless (39.1%) than women (23.9%).  Over half of the 356 
individuals in the study who requested opioid detoxification services, nearly 52%, lacked health 
insurance.  Men requested treatment most often on Mondays, and most contacts occurred between 
8 AM and 4 PM daily.  Women requested treatment most often on Fridays, with over half of the 
contacts during the study occurring between 8 AM and 12 noon. 
 Numerous studies demonstrate that women affected by opioid use disorders (OUD) are 
more likely to suffer from mental health issues and exhibit increased severity of medical and 
mental health issues compared to men.  This increased severity is known as the “telescoping 
effect.”   In a manner consistent with the literature, the analysis of data identified an increased 
percentage of medical and mental health comments on women’s screening forms when compared 
to men.  
 The relative frequency of admission into the opioid detoxification program over the course 
of the study was 1.04 men: 1 woman.  In 2013, the most recent year that national data is available, 
the frequency for opioid detoxification admission in the United States was 1.24 men: 1 woman 
(“TEDS,” 2015). In 2014, Maine’s opioid admission frequency was 1.14 men: 1 woman 
(“DASIS,” 2016).  Nearly 78% of the female admissions in the study either had no insurance 
(42.2%) or had public insurance (35.9%).  Most men admitted lacked insurance (58.1%), and about 
23% were covered by Maine Care/Medicare.   The block grant funding that financed the admission 
of those without insurance available appeared to effectively mitigate the affordability barrier. 
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 The non-admission rate for all clients requesting treatment was 62.4%.  A full program 
capacity prevented the admission of 17% of clients, with equal rates for men and women.  Despite 
the structure limitations present, the availability barrier did not appear to be affect women 
disproportionately. 
 Accommodation as it related to structure also appeared to present a barrier to access.  
However, the Milestone Foundation personnel routinely modified the process, changing nursing 
duties and client room placements to address and correct issues, thereby mitigating the 
accommodation barrier.  The organization also recently implemented a new process to call back 
pregnant women with OUDs when a bed became available in situations where a full capacity 
prevented their admission. 
 When compared to men, women had a slightly higher percentage of non-admission due to 
accessibility issues, with 71.2% of women and 67.9% of men not admitted due to health, legal, or 
transportation issues. 
 While acceptability issues could not be readily identified in the study, specific comments 
consistent with this barrier were only noted on female detoxification inquiry screening forms.  Self-
exclusion, or a failure to initiate the request for detoxification treatment services may be the 
primary limitation to access faced by women, and cannot be identified using the framework set 
forth in this study.  Causes are numerous, and include most, if not all, of the barrier categories in 
the study.  
 The federal funds available through the Affordable Care Act’s Medicaid expansion would 
be beneficial to improving access to opioid detoxification services.  As it stands, Maine’s current 
refusal to receive this distribution prevents the improvements to the detoxification and treatment 
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system, and the increased insurance coverage to Maine’s vulnerable populations that it would 
provide.  It’s estimated that 30% of Maine’s uninsured population suffer from mental illness or 
substance use disorders, and meet the income requirements for coverage under the expanded 
Medicaid coverage of the Affordable Care Act (Dey et al., 2016).  The sixth attempt at attaining 
these funds recently passed both the branches of the Maine Legislature, and a veto from the 
Governor is expected. 
 Based on the results of the capstone study, the Milestone Foundation performs an excellent 
service to its clients.  The results of the study demonstrate that the Milestone Foundation acute 
opioid detoxification program anticipates and mitigates many of the potential barriers to women.  
Milestone Foundation overcomes its structural limitations by utilizing a comprehensive, yet 
flexible process that can be modified to address specific issues.  This is accomplished by 
counteracting deficiencies of specific components in the barrier model with strengths from other 
components in the same category, or with linked components in an associated category.  The 
system appears to mitigate many of the barriers to access that women may encounter.   However, 
barriers that prevent women from initially requesting treatment still present a potential problem.  
Further revisions may be necessary as the prevalence of opioid use disorder in women continue.  
Subsequently, my recommendations to improve processes and enhance women’s access to services 
at Milestone Foundation are as follows: 
1. Reinstitute 24 hour admissions by utilizing The Pharmacy services at Maine Medical 
Center. 
2. Recruit a backup provider with medication assisted treatment (MAT) certification to ensure 
Suboxone (buprenorphine) availability. 
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3. Implement marketing strategies directed towards female clients.  Create and distribute 
brochures, and update the homepage on the website to increase awareness of services for 
women.  Utilize the news media to promote detoxification and treatment services. 
4. Revise the data inquiry screening form to streamline and simplify the process.  Use forms 
on different colored paper to identify gender.   Perform regular audits to ensure that all 
screening forms are completed, and filled out in a standardized manner.   
5. Utilize socio-economic data on the data inquiry screening forms to inform decision making 
and create new grant-writing or funding opportunities. 
6. Access resources available from Maine Quality Counts organization for quality 
improvement and educational webinars. 
7. Future - Implement an electronic system for efficient, accurate screening and admitting 
processes.   
8. Future - Improve telecommunications and increase staffing.  Implement and provide 
staffing for a telephone queue system and an electronic screening/admitting system.  
Recruit retired nurses for per diem assistance during high volume of admissions or 
discharges. 
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Introduction 
A Description of the Problem 
 
Opioid Use Disorder in Maine 
 
Maine is currently experiencing a public health crisis of epic proportions. Compared to 
other states, Maine ranks number one in the nation for the rate of prescribed long-acting/extended-
release opioid pain relievers and eleventh for high-dose opioid pain relievers per 100 persons 
(Paulozzi and Hockenberry, 2014).  The wide availability of prescription opioids has led to a 
substantial increase in the rate of opioid use disorders (OUD) in the state.  In addition, the increased 
availability and decreased cost of heroin has resulted in elevated rates of heroin addiction in Maine 
(“Substance and Mental Health Services - SAMHS,” 2012).  Medical consequences of OUD 
include increased risk of overdose, respiratory and cardiovascular illness, as well as infectious 
diseases like Hepatitis C or HIV (McHugh et al., 2014; Hölscher et al., 2010).   
A grim statistic offered by Maine’s Office of Chief Medical Examiner reveals that from 
2011 to 2014, annual deaths caused by heroin/morphine overdoses rose a staggering 530% 
(“Hornby,” 2015, page 60).  With 57 fatalities, heroin/morphine accounted for 69% of all overdose 
deaths in 2014 (”Hornby,” 2015 page 60).  Emergent Naloxone administration in that same year 
prevented fatal opiate overdoses in 829 cases (”Hornby,” 2015, page 57).  Compared to 2014, the 
number of overdose deaths in 2015 that were attributed to heroin/morphine doubled, with 107 
fatalities documented (Sorg, 2016).  Essentially, deaths doubled in one year from approximately 1 
per week in 2014 to over 2 per week in 2015.  Overdose deaths due to pharmaceutical opioids also 
rose, from 101 fatalities in 2014 to 111 in 2015 (Sorg, 2016).   
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Given these facts and continuing trends, there is little surprise that stakeholders in the 2015 
Maine Shared Community Needs Assessment survey ranked drug and alcohol abuse as the top 
health issue in the state (“Maine Shared Health Needs Assessment & Planning Process - 
SHNAPP,” 2015).  Unfortunately, the availability of detoxification and treatment options in the 
state of Maine is limited and has been unable to keep pace with the high demand for treatment 
services.  Statistics also demonstrate that women are becoming increasingly affected by OUD 
(”DASIS,” 2016; Abuse, 2013).  With these two factors combined, women may be 
disproportionately affected by Maine’s limited access to care and treatment of OUD, essentially 
resulting in a health inequity.  
An Increase in Women’s Incidence of Opioid Use Disorder 
 
 Although less than men, the percentages of women who are admitted for OUD treatment 
are increasing.  In 2011, 44% of heroin detoxification admissions in Maine were female (Abuse, 
2013).  In 2014, the percentage of the state’s female admissions had risen to 46.7%, compared to 
53.3% for men (”DASIS,” 2016).  One cannot easily ascertain if the lower percentage of female 
admissions in Maine compared to men is simply due to a lower number of addictions or if it is 
further exacerbated by limited access to treatment and by barriers to accessing services.  One such 
barrier is noted on the Substance Abuse and Mental Health Services Administration (SAMHSA) 
website which currently lists only 141 physicians in the state who are authorized to treat OUD 
with buprenorphine, of which only 24 physicians are located in Portland (“SAMHSA Physician 
Locator,” 2016).  Despite being certified, many of them are currently not administering medication 
assisted treatment (Farwell, 2015).   
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Respondents in the 2015 Maine Shared Community Needs Assessment survey identified 
the resources needed to address the growing opioid epidemic in Maine which included “greater 
access to drug/alcohol treatments; greater access to substance abuse prevention programs, free or 
low-cost treatments for the uninsured, more substance abuse treatment providers, and additional 
therapeutic programs” (“SHNAPP,” 2015).  In addition to the barriers caused by availability of 
providers, women have specific social and economic issues that may further limit their access to 
OUD services.   
The Milestone Foundation 
 For many people, the first step to accessing treatment services is through a detoxification 
program.  The Milestone Foundation, providing detoxification services for nearly 50 years, is a 
Portland-based organization that is committed to providing medical detoxification to men and 
women with substance use disorders, regardless of their financial or residential situations.  In 
addition to being Maine’s only non-hospital based acute detoxification program, the Milestone 
Foundation is one of few Maine organizations that will admit people into a detoxification program 
without health insurance (R. Fowler, personal communication, January 25, 2016).    
 In 2015, the Milestone Foundation received 2,857 requests for admission into the 
detoxification program.  Milestone Foundation provided acute detoxification services to 1,065 
clients, of which 20% were women (Unpublished Milestone data, 2015). The availability of 
detoxification services to women is dependent on their self-referral and social support, as well as 
their payment options, their geographical access to the program, and on the program’s limited 
capacity for admission.  A barrier in any one or several of these areas may affect women’s access 
to acute opioid detoxification services. 
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Methods 
Evolution of the Capstone Study 
 
Initial Interest 
 
 The Executive Director at Milestone Foundation approached faculty at Muskie School of 
Public Service (Muskie) in the summer of 2015 and requested assistance.  The foundation was 
hoping that the Muskie School could help them analyze the standardized data collected in 
screening forms to help inform decision making and improve processes within the organization.  
Unlocking any of the information in the forms would enable the organization to increase their 
understanding of the program’s client population.   
 My interest in partnering with Milestone Foundation was immediate and compelling; the 
topic of substance use disorders is important to me because I have personal connections with this 
subject matter.  I have witnessed the successful battles with and the continued triumphs over use 
disorders including:  alcohol, opioids, tobacco, and gambling.  Subsequently, I understand the 
devastating effects that substance use disorders can have on health and family, and why there is an 
ongoing need for access to detoxification and treatment services that is so great. 
Capstone Proposal 
 
 My capstone proposal evolved from emails, phone calls, and meetings with the Executive 
Director and the Director of Nursing Services of Milestone Foundation.  The Executive Director 
identified many possible capstones based on the data in the detoxification forms.  One of the 
requests was to gain more understanding about women’s access to their services.  In order to 
control the magnitude of the capstone study, I narrowed this topic by selecting women’s access to 
acute opioid detoxification services specifically. 
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Synthesis of Committee Recommendations 
 
 The initial proposal involved a data analysis, informal interviews with the Executive 
Director and the Director of Nursing Services, and semi-structured interviews with the nursing 
staff who performed the screening and admitting procedures.  At the recommendation of the 
capstone committee, I eliminated the semi-structured interviews, thereby preventing potential 
issues and delays with the Internal Review Board process.  I also revised the working hypothesis 
to reflect the language of a null hypothesis and provided an alternate hypothesis based on their 
suggestions. 
Capstone Study Research Questions 
 
 My capstone study focuses on addressing the following research questions: 
 What is the prevalence of women presenting for OUD detoxification services at Milestone 
Foundation? 
 Is there a difference in the acceptance rate between men and women who present for OUD 
detoxification treatment? 
 What are the barriers to accessing OUD detoxification services in Maine, and are they 
different for men and women? 
Capstone Hypotheses 
Null Hypothesis: 
 
It is hypothesized that there is no significant gender difference in access to OUD 
detoxification treatment services in Maine. 
 
An Analysis of Women’s Access to Opioid Detoxification                                         C o n l e y  |20  
 
 
 
Alternate Hypothesis: 
 
Given the limited availability of detoxification services in the state and the additional 
barriers to treatment faced by women it is hypothesized that when compared to men, 
women are disproportionately affected by the limited access to OUD detoxification 
treatment services in the state of Maine. 
Literature Review 
 A literature review was conducted using URSUS library databases Academic Search 
Complete and PubMed, as well as OpenAthens and Google Scholar.  Numerous searches were 
performed using combinations of the keywords:  Gender, women, substance abuse, substance use 
disorder, opiate/opioid use disorder, opioid, detoxification, and access.  Occasionally, the literature 
provided insights that required accessing the original study cited in the work.  When possible, 
additional relevant publications referenced in the literature citations were accessed and reviewed.  
Study Design 
   
Avedis Donabedian (1988, 2005) described an approach to assess the quality of care that 
is generally known as the primary foundation for healthcare quality.  The model separates 
information into 3 defined classifications of structure, process, and outcome, and identifies the 
prerequisite of optimal linkages between the categories in order for quality to be achieved 
(Donabedian, 2005).  I used Donabedian’s triad to inform my analysis, to aid in categorizing the 
information, and to provide a framework for the summary of the capstone study. 
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Description of Donabedian’s Framework 
 
The structure category describes the contextual aspect of the system and includes 
components such as physical structures, organizational staffing, and insurance availability.  
Process describes the procedures utilized in the system, and the actions taken by all involved.  The 
outcome classification describes effects of the system, and the results of processes (Donabedian, 
1988, 2005).    
Defining and Describing Barriers in the Study 
 
 In their seminal publication, Penchansky and Thomas (1981) refined the concept of access 
in healthcare services by defining and categorizing the concept of access to care into 5 
classifications:  Availability, accessibility, accommodation, affordability and acceptability.  In a 
study set in rural Kentucky, Jackson and Shannon (2012) used four of the five classifications to 
identify barrier categories limiting women’s access to substance use treatment.  Limited capacity 
and gender issues represent availability barriers.  Accessibility barriers include family care and 
responsibility, transportation, health issues preventing entry, or incarceration.  Moreover, 
affordability barriers such as lack of insurance can also prevent access to care. Internal 
acceptability barriers including shame and stigma, as well as fear of consequences and treatment 
difficulties, have also been shown to impact treatment access (Jackson and Shannon, 2012).  
Finally, the fifth classification, accommodation, refers to structural and procedural barriers to 
access such as hours of operation, telecommunications, and the ability or inability to make 
modifications to the system (Penchansky and Thomas, 1981).  All five classifications were utilized 
in this capstone study to identify and categorize barriers to access.  
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Internal Review Board (IRB) Review 
 
 I requested an IRB review prior to implementing the capstone study.  The review deemed 
the study to be Non-Research.  The IRB review response notification is available in Appendix A.  
Data Collection 
 
Detoxification Inquiry Screening Forms and Milestone Statistics 
 
A specific subset of Detoxification Inquiry Screening forms were prescreened and de-
identified by Milestone Foundation staffs and only the forms of individuals who requested 
detoxification from opioid use were utilized in this analysis.  A blank sample of the detoxification 
inquiry screening form is illustrated in Appendix B.  I reviewed and analyzed all forms provided.  
Opioid detoxification inquiry screening form data that had been previously collated by Milestone 
staffs were also assessed for the same selected time frames.  
Time Frame 
 
 The analysis comprised a six month review of requests for opioid detoxification admission, 
using the data available on the detoxification inquiry screening form and data obtained from the 
Milestone Foundation.   In order to demonstrate trends by implementing an analysis over time, and 
to account for any seasonal variation, data were reviewed for the months of January, February, 
June, and July of 2015, and January and February of 2016. 
Data Table Shells 
 
 Two data table shells were used to collate the data.  The first table was used to document 
information from the detoxification inquiry screening forms. A representative table is illustrated 
in Table 1, with all comments removed.  The first iteration of Data Table Shell #1 also had a 
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column for admissions and non-admissions.  However, these data collection points were later 
removed because the admission information was often unavailable or incomplete on the 
detoxification inquiry screening form.  
 
Table 1. Data Table Shell #1. 
 
 
 
The data provided from Milestone Foundation was categorized using a separate table, as illustrated 
below in Table 2.  Both complete data sets are available in Appendices C and D. 
 
Table 2. Data Table Shell #2. 
 
 
 
Data Analysis 
 
 A total of 196 detoxification inquiry screening forms as well as data from 356 requests for 
detoxification were analyzed.  Since each data set contained unique information, both data sets 
8a-12n 12:01-4p 4:01-8p YES, Private YES, Public NO
F 2/1/2016 Mon P X X X
M 2/1/2016 Mon W X X X
M 2/2/2016 Tues W UNK UNK UNK X X
F 2/3/2016 Wed UNK UNK UNK UNK X X
F 2/3/2016 Wed P UNK UNK UNK X
M 2/3/2016 Wed P X X X
M 2/3/2016 Wed P X (05:00) X
M 2/3/2016 Wed P X X X
F 2/5/2016 Fri P X X
M 2/5/2016 Fri P X (22:00) X X
M 2/5/2016 Fri P X X X
M 2/7/2016 Sun P X X
M 2/7/2016 Sun P X X
M 2/7/2016 Sun P X X
M 2/8/2016 Mon P X (07:45) X
F 2/9/2016 Tues P X X
M 2/9/2016 Tues P X X
F 2/10/2016 Wed P X X X
M 2/10/2016 Wed P X X X
M 2/10/2016 Wed P X X
F 2/11/2016 Thurs P X X X
F 2/11/2016 Thurs P X X
F 2/12/2016 Fri UNK UNK UNK UNK X
Homeless Comments
Gender 
(M/F)
Date
Day of 
Week
Mode of Contact 
(Phone/ Walkin)
Time of Inquiry Health Insurance
Month- Year Gender Resolution Substance Insurance Repeat Client
Jan-15 female Ct admitted to Detox Opiate Yes (private insurance) no
Jan-15 Female No Admit/Show/Call back Opiate No insurance no
Jan-15 Female No Admit/Show/Call back Opiate No insurance no
Jan-15 Female Program Full Opiate No insurance no
Jan-15 female Ct admitted to Detox Opiate Yes (private insurance) yes
Jan-15 female legal or medical apt that would prevent completion Opiate No insurance yes
Jan-15 female No Admit/Show/Call back Opiate No insurance yes
Jan-15 Female No Admit/Show/Call back Opiate Yes (Mecare/medicare) yes
Jan-15 Male Ct admitted to Detox Opiate No insurance no
Jan-15 Male Ct admitted to Detox Opiate No insurance no
Jan-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
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were utilized concurrently in the study for various quantitative analyses.  Whenever possible, I 
compared the percentages that were generated by the screening forms with those generated from 
the Milestone data to confirm the relevance and accuracy of both statistics.  The data was assessed 
in monthly increments and in toto.   
Comparisons 
 
 Monthly and overall statistics that were generated from the two data sets were compared 
by gender, and included: 
 Selected client demographics – days and times of request, residential and financial status 
 Total and weighted percentages of requests for treatment 
 Total and weighted percentages of admissions  
 Prevalence and incidence of requests for treatment and admissions 
 Total and weighted frequencies of requests for treatment, admissions and non-admissions 
 Percentages and causes of non-admissions 
Triangulation and Synthesis 
 
 Results were assessed in relation to available state, national, and literary data.  Non-
admissions were categorized in accordance with the 5 access classifications of Penchansky and 
Thomas (1981), and Donabedian’s framework of structure, process and outcome. 
Limitations 
 
 The capstone study was limited by several factors that may affect the validity of findings. 
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Structure 
 
 The Milestone Foundation detoxification program is limited by program capacity and 
available nursing staff.  These limitations may affect admission statistics.  Since most requests 
occur through telecommunications, results are also limited by the number of phones.  Additionally, 
located in Portland, the Milestone Foundation is situated in the lower tip of Maine.  Client 
population may be affected, as clients may self-select or exclude based on the vast geographical 
distances found in Maine, and by state demographics.   
Process 
 
 The program is limited by specific hours of admission, which may impact admission 
statistics.  In addition, the study begins with the Milestone Foundation detoxification inquiry 
screening form that is initiated when the client requests detoxification treatment.  Subsequently, 
any barriers to access that are related to the individual’s actions, or that occur prior to the initial 
request for service cannot be identified; because these barriers may or may not be readily apparent 
there is a potential that they may affect the data.  Moreover, these analyses were based on data 
handwritten by numerous Milestone Foundation nursing staffs.  Some forms were incomplete, and 
there appears to be some variation in the screening process.  This adds a level of uncertainty to the 
data.  Finally, a form was initiated for each request, regardless of whether the individual had made 
a recent prior request for services.  Each request was identified as one request for treatment; 
multiple requests by one individual over the period of time reviewed could potentially skew the 
data.    
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Outcome 
 
 Results of the study are based on data obtained for clients who requested detoxification 
services related to opioid use only.  Clients also presented who requested detoxification from 
multiple substances that included opioids.  This data was excluded from the study, which may 
affect the percentages yielded in the analysis. Additionally, requests for admission are received 
from several New England states due to the physical location of the Milestone Foundation, as well 
as the limited numbers of programs available in New England.  Although the number of requests 
from out-of-state clients in the study was minimal, data obtained is not limited strictly to Maine 
citizens, and may affect comparisons with Maine data. It is also important to note that data on 
opioid use disorder in Maine is not readily accessible, and when available, the most recent data is 
several years old.  Comparisons and references are limited by data availability.   
Context 
Maine’s Lack of Access to Detoxification and Treatment Services 
 
 The lack of access to substance abuse treatment is a recurring theme in the state of Maine.  
Using Donabedian’s framework, this issue may be identified primarily as a structural problem.  
Currently, there are only 14 residential treatment facilities in the state and 7 (50%) of them are in 
Cumberland County.  In addition to limited residential treatment options, Maine has a severe 
shortage of providers and facilities offering outpatient services for mental health and substance 
use disorders, especially in its rural areas.  In 2002, the Office of Substance Abuse (OSA), the 
Maine Center for Public Health (MCPA), and the Maine Public Health Association (MPHA) 
convened a task force to address an opiate epidemic in the state.  The MCPH/OSA Opiate Abuse 
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and Overdose Task Force identified specific recommendations on access to treatment, based on 
the structural limitations of treatment services:  
 “Increase access to treatment, including overdose care, pharmacological treatments (such 
as methadone and newer office-based treatments such as Buprenorphine), detoxification 
services where appropriate and long-term treatment, such as therapeutic communities. 
 Identify existing barriers and implement actions to improve access to treatment” (Conway, 
2002). 
 
 Statistics are often utilized to identify generalized prevalence of substance use disorder or 
to demonstrate trends over time.  The increased rate of admissions over time appears to be 
indicative of increased abuse in the population and not necessarily in increased accessibility to 
services.  For example, between 2001 and 2011, total admissions for non-heroin opiates and 
synthetics treatment rose 345% in Maine as 
noted in Figure 1 (Abuse, 2013).   
Between 2009 and 2014, the estimated 
number of individuals in Maine who used any 
illicit drug in the previous month increased by 
245% (“NSDUH,” 2015).  At the same time, 
estimated numbers of those needing but not 
receiving treatment within the past year 
dropped only 4% (“NSDUH,” 2015).  Between 2010 and 2014, only 19% of all Maine individuals 
who needed treatment for illicit drug use received it within the previous year (“SAMHSA,” 2016).  
Comparatively, from 2009 to 2013, single-day counts of people enrolled in buprenorphine 
0
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Maine Non-heroin 
opiates/synthetics admissions
Figure 1. Total admissions for non-heroin 
opiates/synthetics in Maine. 
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treatment services in Maine rose only 16.9%.  Other New England states averaged a 97% increase, 
with single-day count increases ranging from 33% in Vermont to approximately 151% in New 
Hampshire (“SAMHSA,” 2015).  Single-day counts for methadone treatment enrollment during 
that same time frame yielded similar lackluster results for Maine, with an increase of only 7.7% in 
the state.  Increases in the other New England states ranged from 13% in Rhode Island to nearly 
90% in Vermont (“SAMHSA,” 2015).  Further review is needed to determine whether the poor 
enrollment numbers in Maine occur due to barriers in Maine’s treatment structure, deficiencies in 
the process of care, or both.  
The Milestone Foundation Detoxification Program (Structure) 
Physical Structure 
 
 The Milestone Foundation detoxification program is housed in a three-story building 
located on India Street in Portland.  On the ground floor of the building, the organization runs an 
emergency 41-bed specialty substance use shelter that is accessible from the street.  Homeless men 
can wash their clothes, take a shower, eat a hot meal, and sleep safely.  If they are willing, they 
can also request detoxification services (“Milestone Foundation,” 2015).  The first floor contains 
administrative and medical offices, as well as conference and therapy rooms.  The acute 
detoxification unit is located on the second floor.  The medically managed unit contains 16 beds:  
2 ward rooms with 5 beds, and 2 ward rooms with 3 beds.  An office, a storage area, and a nursing 
station are also located on the second floor.  Stairs link all the floors together.  All doors are locked 
externally as a security measure, although are able to be opened from the inside.  It is important to 
note that the client’s admission for treatment is voluntary, and subsequently, all are free to 
voluntarily discharge from the program at any time.  
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Organizational Structure 
 
 A Board of Directors comprised of 11 members oversees the Milestone Foundation 
organization.  Daily administrative operations are controlled by the Executive Director.  Other 
leadership roles at the Milestone Foundation are the Director of Nursing, Director of Finance and 
Administration, Director of Development, and Director of Community Outreach.  Secondary 
leadership positions include the Shelter Manager, 2 Clinical Team Leaders, and the Operations 
Manager who oversees the Extended Care Program located in Old Orchard Beach (“Milestone 
Foundation,” 2015). 
Financial Structure 
 
 The Milestone Foundation is a 501(c) (3) nonprofit organization, with an annual budget of 
approximately 3 million dollars (R. Fowler, personal communication, April 7, 2016).  The program 
is funded in part by state/federal block grants, foundations, and private donors.  It is primarily the 
state/federal block grants that allow Milestone to provide services to those without insurance (R. 
Fowler, personal communication, April 7, 2016).  Private insurance, MaineCare, and Medicare 
also help pay for services (R. Fowler, personal communication, January 25, 2016).  Additional 
funding is received from City of Portland, as well as support from Portland Downtown and Mercy 
Hospital.  Maine State Housing helps to fund the shelter (R. Fowler, personal communication, 
April 7, 2016).  Clients who are out-of-state residents are charged $270.21 on admission, which is 
the cost for their first night in detox (L. Wert, personal communication, April 4, 2016).  A payment 
plan is available for the duration of the stay for out-of-state clients who lack insurance. 
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 Medical and Behavioral Health Support Structure 
 
 A Medical Director leads the medically managed detoxification program.  The physician 
is certified to treat opioid use disorders with buprenorphine, also known as Suboxone.   A Physician 
Assistant provides back-up coverage as needed, although is unable to prescribe Suboxone as 
medication assisted treatment (L. Wert, personal communication, April 4, 2016).  
Nursing Structure  
 
  The detoxification program operates 24 hours a day, 7 days a week.  The Director of 
Nursing supervises a diverse staff of nursing professionals to ensure that the acute program runs 
smoothly and clients are safely detoxified. The nursing pool consists of 6 full-time nurses (4 day 
nurses, 2 night nurses), a number of per diem nurses, 2 full-time CNAs (1 day and 1 night CNA), 
3 part-time night CNAs, several per diem day CNAs, and a Unit Coordinator/CNA (R. Fowler, 
personal communication, January 25, 2016). 
 The acute detoxification program is staffed by various levels of nursing personnel 24 hours 
a day.  Work shifts occur in 12 hour increments, with shift changes at 7 am and 7 pm.  A day shift 
workforce consists of 1 Charge Nurse, 1 Admitting Nurse, and 1 CNA.  During the 
evening/overnight shift, the unit is staffed by 1 Charge Nurse and 1 CNA (L. Wert, personal 
communication, April 4, 2016).   
Behavioral Health Support  
 
 The Milestone Foundation employs 2.5 Substance Use Counsellors.  The counsellors 
perform individual and group counselling, and are responsible for coordinating all aspects of the 
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clients’ case management and aftercare planning (“Milestone Foundation,” 2015; R. Fowler, 
personal communication, January 25, 2016).  
Screening and Admitting Procedures (Process) 
 
 Clients request acute detoxification services for one or a combination of several addictive 
substances that may include alcohol, marijuana, cocaine, opioid, methadone or benzodiazepines.   
Screening 
 
 First contact with the detoxification program may occur by phone, walk-in or through the 
shelter.  During the day, an administrative employee covers the front desk - fielding phone calls, 
and directing clients who walk in.  The telecommunications system includes a phone tree with 2 
lines for detoxification requests.  There are 2 telephones in the nursing station.  Another person 
may make the initial contact on the client’s 
behalf, however a Milestone Foundation staff 
must talk directly to the client during the 
screening procedure (L. Wert, personal 
communication, January 25, 2016).   
 The first page of the detoxification 
inquiry screening form is completed during 
the screening process.  The form is based on 
the American Society of Addictive Medicine 
(ASAM) multidimensional assessment 
criteria shown in Figure 2.  Specific 
Figure 2. ASAM:  The Six Dimensions of Multidimensional 
Assessment. 
www.asam.org 
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assessments in the initial screening cover aspects of the first three dimensions, and are designated 
as D-1, D-2 and D-3 on the screening form.    
 The screening consists of client information, and demographics such as age and gender. 
Several socio-economic markers are requested during the screening, as the staff will determine the 
client’s residency, homeless status, medical insurance coverage, and ability to read and write.  A 
comprehensive substance use questionnaire is completed verbally that includes drug type, route of 
intake, amount, frequency, and date/time of last use.  The age of onset for alcohol or drug use is 
also obtained.  The client is screened for selected medical conditions such as seizures, chest pain, 
pregnancy and gastrointestinal bleeding. Mental health status is assessed by identifying presence 
or absence of a mental health diagnosis or suicidal ideation.  On average, the entire screening 
assessment is completed in about 10 to 15 minutes (L. Wert, personal communication, January 25, 
2016).   
 Based on the screening, the client may be approved for admission, approved contingent on 
a medical clearance, referred to another medical or behavioral facility, or not admitted.  Non-
admission may be due to behavioral problems, a full program capacity, or self-refusal of 
admission.  Anecdotally, 95% of requests meet the criteria for admission (R. Fowler/ L. Wert, 
personal communication, January 25, 2016).  If approval for admission has been given and a bed 
is available, the client is accepted for admission.  The bed will be reserved for that client for the 
amount of time necessary for immediate transportation to the facility.  Although some concessions 
are possible if the client has unforeseen issues in transit, this guideline is strictly enforced due to 
the high demand for detoxification services, and the potential for no-shows.  
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Admission  
 
 The admitting procedure is performed from 8 AM to 8:30 PM.  During the day shift, this 
process is completed by the Admitting Nurse.  On the evening shift, the Charge Nurse will perform 
the admission.  
 The admission procedure is manually documented, and can take from 45 minutes to 3 hours 
(L. Wert, personal communication, January 25, 2016).  All initial screening data is reviewed for 
validity.  Vital signs are measured.  For opioid detoxification, the admitting nurse will perform an 
initial Clinical Opiate Withdrawal Scale, or COWS assessment to rate withdrawal symptoms in a 
standardized manner.   The Medical Director is notified, and a medication protocol is implemented. 
 The client is monitored closely for the first 24 hours. Observations occur every few hours, 
then increase to every six hours, and then expand to three times per day for the duration of the 
admission.  The client is medically assessed by the doctor within 48 hours of admission (L. Wert, 
personal communication, January 25, 2016).   
 A typical detoxification stay lasts between 3 to 7 days.  The detoxification process is 
generally shorter for opioids than for other substances due to differences in the associated 
medication protocols.  While in the detoxification program, the client attends 3 group meetings 
daily, a morning AA meeting, and individual counselling.  The client is given information on 
resources, and if available, aftercare is coordinated for assistance after detoxification is complete 
(R. Fowler/ L. Wert, personal communication, January 25, 2016; R. Fowler, personal 
communication, April 7, 2016).  
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Results (Outcome) 
Requests for Opioid Detoxification 
 
 Over the time frame of the study, 356 individuals requested opioid detoxification treatment. 
Phone calls were the mode of contact for 92% of the requests. The clients consisted of 252 men 
and 104 women, resulting in a relative frequency of 2.42 men: 1 woman requesting treatment.  
Table 3 illustrates the raw data for admission requests by month, which are then weighted for 2015 
population demographics.  In 2015, Maine’s population was 49% male and 51% female (“U.S. 
Census,” 2016).  The observed proportion of men in the study was 70.8%, and women accounted 
for 29.2% of the clients requesting treatment.  Subsequently, males were given a weight of 0. 69, 
and females received a weight of 1.75. 
 
Table 3. Weighted percentages and frequencies of clients requesting treatment, by gender and month. 
 
 
An interesting note in this data is the flip in weighted frequency that occurred during the summer 
months.  This is illustrated in Figure 3 on the following page. 
 
 
Male Female TOTAL
Weighted 
Male
Weighted 
Female
Percentage 
Weighted 
Male
Percentage 
Weighted 
Female
Weighted 
Frequency 
Male:Female
January 2015 21 8 29 14.49 14.00 50.0% 48.3% 1.04:1
February 2015 31 10 41 21.39 17.50 52.2% 42.7% 1.22:1
June 2015 48 19 67 33.12 33.25 49.4% 49.6% 0.99:1
July 2015 31 30 61 21.39 52.50 35.1% 86.1% 0.41:1
January 2016 66 17 83 45.54 29.75 54.9% 35.8% 1.53:1
February 2016 55 20 75 37.95 35.00 50.6% 46.7% 1.08:1
TOTAL 252 104 356 173.88 182
Month
Requesting Treatment
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One questions whether this flip is a seasonal occurrence or if results were skewed by an increased 
number of requests.  A continued review of the data over time may identify this as a trend or a 
deviation from the norm.  With the data intact, the average weighted frequency of requests for 
admission is 1.05 males: 1 female.  Removal of the summer data yields an average weighted 
frequency of 1.22 males:  1 female. 
 Of those individuals requesting detoxification services, 39.1% of the men were homeless, 
compared to 23.9% women.  Insurance status was available on both data sets.  This provided an 
opportunity to confirm correlation of the data while determining the statistics.  As demonstrated 
in Table 4 on the following page, the percentages were similar with the exception of female 
requests with public insurance.  The data tends to support the 35.9% result obtained from the data 
Figure 3. Weighted frequency of requests for admissions. 
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inquiry screening forms as the accurate value.  With the close correlations of all the other 
percentages, and 6.7% of the statuses missing from each gender of the Milestone Foundation data 
set, the Milestone Foundation percentage is in question. 
 
 
 
 The insurance status data demonstrates that nearly 60% of men requesting opioid 
detoxification lacked health insurance.  The remaining clients were divided relatively equally 
between public and private insurance.  At 42%, most women in the study had no insurance, 
followed closely by those with public insurance at 36%.  Only about 1 in 5 women requesting 
treatment had private insurance.  
 Men and women tended to request admission most frequently on different days and at 
different times.  A review of the detoxification inquiry screening forms determined that men 
requested admission most often on Mondays.  Most contacts from men occurred in similar 
percentages between 8am and 12 noon, and 12:01pm and 4pm.  Women requested admission most 
often on Fridays, and over half of the daily contacts occurred between 8am and 12 noon.  Total 
percentile data are noted in Tables 5 and 6. 
 
 
MF data DISF MF data DISF MF data DISF
Male 54.8% 57.8% 21.8% 20.3% 16.7% 18.0% 6.7%
Female 44.2% 42.2% 29.8% 35.9% 19.2% 21.9% 6.7%
MF 
Unknown
Insurance Status of Clients Requesting Treatment
No Insurance Public Insurance Private Insurance
Table 4. Comparison of Milestone Foundation (MF) and detoxification inquiry screening form (DISF) data:  
Insurance status of clients requesting treatment, by gender.  
 
An Analysis of Women’s Access to Opioid Detoxification                                         C o n l e y  |37  
 
 
 
 
 
 
 
 
 
 
 
Women’s Requests for Detoxification Services at Milestone Foundation 
 
Prevalence 
 
 The prevalence of women requesting any detoxification service at Milestone Foundation 
during the study’s time period was 366 women out of 1,366 clients, or 26.8%, compared to 73.2% 
of men requesting treatment.  The analysis demonstrated that the prevalence for women requesting 
opioid detoxification specifically improved slightly in comparison:  104 women out of 356 clients 
in the study yielded a prevalence of 29.2% for women compared to 70.8% of men. 
8a to 12n 12:01 to 4p 4 to 8p
Time Fell Outside 
of These Ranges
Male 41.6% 38.1% 5.8% 10.6%
Female 53.8% 28.8% 9.7% 11.5%
Time of Contact
Sunday Monday Tuesday Wednesday Thursday Friday Saturday Unknown
Male 15.6% 21.1% 10.9% 14.8% 17.2% 14.8% 5.5% 0.0%
Female 9.4% 7.8% 14.1% 14.1% 15.6% 21.9% 14.1% 3.1%
Requests for Admission by Day
Table 5. Percentages of contact, by gender and time range. 
Table 6. Percentages of contact, by gender and day. 
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Incidence 
 
 The data identified if the individual had been admitted to the program previously.  The 
incidence was calculated based on the numbers of clients who were not returning clients:  They 
were either not admitted on previous requests or they were requesting treatment for the first time.  
These clients were designated as “new requests” for simplicity.  The number of days in each month 
in the study was totaled and the results were calculated to determine the incidence per year.  
Subsequently, the specific months selected in the study yielded 180 days.  New detoxification 
requests from males occurred in 150 of the 252 requests for admission, or 59.5%.  The incidence 
for men was 304 new requests per year.  New requests from females occurred in 75 of the 104 
requests for admission, or 72.1%.  The incidence for women was 152 new requests per year.  The 
relative frequency of new requests was 2.00 men: 1 woman. 
The Acceptance Rate of Men and Women 
 
Much of the available data on OUD is related to treatment.  Subsequently, national and 
state comparisons could only be performed with analyses of the admissions data.  During the 6 
months of the study, 96 men and 38 women were admitted into the opioid detoxification program.  
Table 7 below illustrates the percentages of admissions by month, and corresponding admission 
trends are depicted in Figure 4 on page 39.  The relative frequency of admission into the opioid 
detoxification program over the course of the study was 1.04 men: 1 woman.  In 2013, the most 
recent year that national data is available, the frequency for opioid detoxification admission in the 
United States was 1.24 men: 1 woman (“TEDS,” 2015). In Maine, the relative frequency for 
admission for any opioid use disorder in 2013 was 1.10 men: 1 woman.  In 2014, Maine’s opioid 
admission frequency increased to 1.14 men: 1 woman (“DASIS,” 2016).  Compared to the state 
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and national data available, Milestone Foundation’s admission frequency demonstrated no 
apparent access barrier for female clients. 
 
 
Although a laudable goal, a 100% admission rate is unachievable, and unlikely.  Still, the 
trend lines of both male and female admissions in Figure 4 on the next page demonstrate that the 
admission rates are rising.  Women’s percentages of admissions appear to be rising at a higher rate 
than men, and based on the trend lines, at a trajectory of about 5:1, meaning that for every 1% rise 
in male admissions, women’s admissions rise by 5%.  This may be a reflection of the lower number 
of women requesting treatment, which would increase the weight of their admissions in the 
calculations, or an indication that women’s access may be improving, and the percentages are in 
fact approaching an equal amount.   
 
 
 
Males 
Admitted
Males 
Requesting 
Admission
Percentage 
Males 
Admitted
Females 
Admitted
Females 
Requesting 
Admission
Percentage 
Females 
Admitted
January 2015 9 21 42.9% 2 8 25.0%
February 2015 9 31 29.0% 4 10 40.0%
June 2015 15 48 31.3% 7 19 36.8%
July 2015 13 31 41.9% 7 30 23.3%
January 2016 27 66 40.9% 8 17 47.1%
February 2016 23 55 41.8% 10 20 50.0%
TOTAL 96 252 38.1% 38 104 36.5%
Clients Admitted Into the Detoxification Program
Month
Table 7. Percentages of admissions, by gender and month. 
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Consistent with the requests for admission, the admission data were weighted to account 
for Maine’s 2015 population demographics.  The results are noted in Table 8. 
 
 
 
 
Males 
Admitted
Females 
Admitted
TOTAL
Weighted 
Male 
Admissions
Weighted 
Female 
Admissions
Percentage 
Weighted 
Male 
Admissions
Percentage 
Weighted 
Female 
Admissions
Weighted 
Frequency 
Male: Female
January 2015 9 2 11 6.21 3.50 56.5% 31.8% 1.78:1
February 2015 9 4 13 6.21 7.00 47.8% 53.8% 0.89:1
June 2015 15 7 22 10.35 12.25 47.0% 55.7% 0.84:1
July 2015 13 7 20 8.97 12.25 44.9% 61.3% 0.73:1
January 2016 27 8 35 18.63 14.00 53.2% 40.0% 1.33:1
February 2016 23 10 33 15.87 17.50 48.1% 53.0% 0.91:1
TOTAL 96 38 134 66.24 66.50
Month
Clients Admitted Into the Detoxification Program
Table 8. Weighted percentages and frequencies of admissions, by gender and month. 
 
Figure 4. Percentages of clients admitted, by gender, with trend line. 
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Figure 5 illustrates the weighted frequency of admissions over the course of the study.  The trend 
line demonstrates that, when weighted for population, the frequency of opioid detoxification 
admissions for women have generally equaled or surpassed those of men since July 2015. 
 
 
 
Prevalence 
 
 The prevalence of female admissions for opioid treatment during the analysis time frame 
was 38 admissions out of 134 total admissions, or 28.4% of the admissions were women, compared 
to 71.6% men.  This prevalence rate was similar to that demonstrated for admission requests.  
Incidence 
 
 The incidence of admissions was also similar to the incidence of requests for admission.  
New requests accounted for 54 of male admissions in 180 days, for an incidence of 110 men 
Figure 5. Weighted frequency of admissions, with trend line. 
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admitted per year.  Of the 38 women admitted, 28 were new requests, yielding an incidence of 57 
female admissions per year.  The relative frequency of new request admissions was 1.93 men: 1 
woman. 
Non-admissions 
 
 During the 6 months analyzed, 222 clients seeking treatment were not admitted, resulting 
in a non-admission rate of 62.4%.  No Shows/No Callbacks accounted for 130, or nearly 60% of 
clients not admitted.  A full program capacity prevented the admission of 17% of clients.  The non-
admission data are presented in Table 9. 
 
 
 
 
Non-admission data were weighted for Maine’s 2015 population demographics and the weighted 
frequencies were calculated.  The results are displayed in Table 10 on page 43. 
 
Males Not 
Admitted
Males 
Requesting 
Admission
Percentage 
Males Not 
Admitted
Females 
Not 
Admitted
Females 
Requesting 
Admission
Percentage 
Females Not 
Admitted
January 2015 12 21 57.1% 6 8 75.0%
February 2015 22 31 71.0% 6 10 60.0%
June 2015 33 48 68.8% 12 19 63.2%
July 2015 18 31 58.1% 23 30 76.7%
January 2016 39 66 59.1% 9 17 52.9%
February 2016 32 55 58.2% 10 20 50.0%
TOTAL 156 252 61.9% 66 104 63.5%
Month
Clients Not Admitted Into the Detoxification Program
Table 9. Non-admissions, by gender and month. 
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Figure 6 illustrates the trend over time.  In this instance, a rising trend line, as seen here, indicates 
that the frequency of male non-admissions is increasing, or that those of women are decreasing. 
 
 
 
Causes for Non-admissions 
 
 The causes for non-admissions noted in the study are identified and tabulated in Tables 
11 and 12 on the following pages. 
Male Female TOTAL
Weighted 
Male
Weighted 
Female
Percentage 
Weighted 
Male
Percentage 
Weighted 
Female
Weighted 
Frequency 
Male: Female
January 2015 12 6 18 8.28 10.50 46.0% 58.3% 0.79: 1
February 2015 22 6 28 15.18 10.50 54.2% 37.5% 1.45: 1
June 2015 33 12 45 22.77 21.00 50.6% 46.7% 1.08: 1
July 2015 18 23 41 12.42 40.25 30.3% 98.2% 0.31: 1
January 2016 39 9 48 26.91 15.75 56.1% 32.8% 1.71: 1
February 2016 32 10 42 22.08 17.50 52.6% 41.7% 1.26: 1
TOTAL 156 66 222 107.64 115.5
Clients Not Admitted Into the Detoxification Program
MONTH
 
Table 10. Weighted percentages and frequencies of non-admissions, by gender and month. 
Figure 6. Weighted frequency of non-admissions, with trend line. 
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Total 
Male
89 57.1% 26 16.7% 14 9.0% 3 1.9% 10 6.4%
15-Jan 4 33.3% 2 16.7% 2 16.7% 0 0.0% 1 8.3%
15-Feb 7 31.8% 9 40.9% 1 4.5% 1 4.5% 2 9.1%
15-Jun 22 66.7% 3 9.1% 2 6.1% 0 0.0% 2 6.1%
15-Jul 7 38.9% 6 33.3% 1 5.6% 1 5.6% 1 5.6%
16-Jan 27 69.2% 5 12.8% 2 5.1% 0 0.0% 4 10.3%
16-Feb 22 68.8% 1 3.1% 6 18.8% 1 3.1% 0 0.0%
Total 
Male
7 4.5% 1 0.6% 2 1.3% 4 2.6%
15-Jan 2 16.7% 1 8.3% 0 0.0% 0 0.0%
15-Feb 0 0.0% 0 0.0% 0 0.0% 2 9.1%
15-Jun 2 6.1% 0 0.0% 1 3.0% 1 3.0%
15-Jul 2 11.1% 0 0.0% 0 0.0% 0 0.0%
16-Jan 1 2.6% 0 0.0% 0 0.0% 0 0.0%
16-Feb 0 0.0% 0 0.0% 1 3.1% 1 3.1%
33
18
39
32
Cannot Admit 
With Current 
Client
Causes for Male Client Non-admission Into the Detoxification Program 
Causes for Male Client Non-admission Into the Detoxification Program 
156
12
22
Month Total Not 
Admitted
Self-Refused Behavior Issue
Inquiry Not 
Complete
Month
No 
Admit/show/ 
call back
Program Full
Medical 
Clearance/ 
Higher Level of 
Care
Legal/Medical 
Appointment
Detox 
Requested and 
Not Needed
 
Table 11. Causes for non-admission of male clients, total and percentile by month. 
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Total 
Female
41 62.1% 11 16.7% 4 6.1% 2 3.0% 1 1.5%
15-Jan 4 66.7% 1 16.7% 0 0.0% 1 16.7% 0 0.0%
15-Feb 3 50.0% 1 16.7% 0 0.0% 0 0.0% 1 16.7%
15-Jun 9 75.0% 3 25.0% 0 0.0% 0 0.0% 0 0.0%
15-Jul 14 60.9% 2 8.7% 2 8.7% 1 4.3% 0 0.0%
16-Jan 3 33.3% 4 44.4% 1 11.1% 0 0.0% 0 0.0%
16-Feb 8 80.0% 0 0.0% 1 10.0% 0 0.0% 0 0.0%
Total 
Female
3 4.5% 1 1.5% 1 1.5% 2 3.0%
15-Jan 0 0.0% 0 0.0% 0 0.0% 0 0.0%
15-Feb 0 0.0% 0 0.0% 0 0.0% 1 16.7%
15-Jun 0 0.0% 0 0.0% 0 0.0% 0 0.0%
15-Jul 3 13.0% 1 4.3% 0 0.0% 0 0.0%
16-Jan 0 0.0% 0 0.0% 1 11.1% 0 0.0%
16-Feb 0 0.0% 0 0.0% 0 0.0% 1 10.0%
Causes for Female Client Non-admission Into the Detoxification Program 
No Admit/show/ 
call back
Program Full
Medical 
Clearance/ 
Higher Level of 
Care
Legal/Medical 
Appointment
Month Detox Requested 
and Not Needed
Month
Causes for Female Client Non-admission Into the Detoxification Program 
Self-Refused Behavior Issue
Inquiry Not 
Complete
Cannot Admit 
With Current 
Client
Total Not 
Admitted
10
66
6
6
12
23
9
 
Table 12. Causes for non-admission of female clients, total and percentile by month. 
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Women and Acute Opioid Use Disorder 
The Severity of Women’s Issues 
 
 Addicted women are more likely to suffer from mental health issues (Grella, 2008; 
Greenfield et al., 2006; Back et al., 2011; Taylor, 2010).  Psychopathology studies have 
demonstrated that women are more likely to exhibit negative internalizing mental health behaviors 
such as anxiety, eating disorders and depression, whereas men are more likely to demonstrate 
externalizing actions: aggression or impulsive behaviors. (Hecksher and Hesse, 2009).  Substance 
use disorder (SUD) is generally considered the manifestation of an externalizing behavior (Zucker, 
2008).  Subsequently, the disparity experienced by women who display an externalizing behavior 
such as OUD may intensify the severity of physical and mental health issues that they encounter 
(Hecksher and Hesse, 2009).  This increased severity of issues is known as the “telescoping effect,” 
and is well documented in the literature. 
Telescoping Effect 
 
Gender-specific telescoping effect has been noted in substance use disorders, whereby 
women begin using substances later in life, yet progress more quickly to the harmful consequences 
caused by SUD.  An early study by Piazza et al. (1989) demonstrated that the onset and progression 
of severity of SUDs were more rapid in women than in men.  In a comprehensive literature review, 
Green (2006) described this telescoping effect in women who suffer from SUD.  A separate study 
on opioid use disorders in six multinational European cities demonstrated a limited telescoping 
effect between men and women (Hölscher et al., 2010).  Different telescoping effects by gender 
were noted when the age of onset was matched and duration of past consumption was limited to 4 
years.  The researchers noted that women had increased onset of family and social problems, and 
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men had more incidence of economic and legal issues (Hölscher et al., 2010).  Such telescoping 
was not noted when duration of use reached 11 and 15 years and the severity of dependence was 
similar (Hölscher et al., 2010).   
Prescription Opioid Abuse 
 
 Women’s increased severity of medical and mental health problems are also noted in the 
literature.  Back et al. (2011) demonstrated that women’s self-reported cravings for opioids were 
significantly higher than men. In addition, the analysis utilized a concurrent medical history that 
demonstrated an increase in female medical and psychiatric issues when compared to men (Back 
et al., 2011).  In a study of national hospital admissions between 1993 and 2009, Unick et al. (2013) 
identified that women had higher rates of prescription opioid-related overdoses than men in every 
year reviewed.  A 2014 Treatment Episode Data Set (TEDS) report by SAMSHA described 
differences in illicit prescription opioid use by age and gender.  The report assessed 2011 data, and 
noted that in the age groups of 25 – 34, and 65 and older, women had higher proportions of opioid 
admissions.  In the elder category, the percentage of female admissions was 3 times that of men 
(“TEDS,” 2014).  Evans et al. (2015) assessed opioid use mortality by gender using standardized 
mortality ratios (SMR).  The study demonstrated that when compared to the general population, 
women with opioid use disorders had a greater increased risk of mortality than men (Evans et al., 
2015).   
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Barriers to Access 
 
 By describing and categorizing barriers to access, we can refine our understanding of these 
barriers.  We are then able to increase the potential to eliminate any barriers to accessing opioid 
detoxification services as we identify associations among and between the barriers. 
Internal and External Barriers 
 
 Comparable to internalizing and externalizing behaviors, one can easily identify barriers 
relating to access to treatment as either internal or external.  Internal or intrinsic barriers to access 
are developed within the individual through actions and beliefs, while external or extrinsic barriers 
to access are those caused by systems or processes in the individual’s surroundings (Hecksher and 
Hesse, 2009).   
A Synthesis of 3 Concepts  
 
 The 5 classifications of access that Penchansky and Thomas (1981) describe may be 
categorized as external or internal barriers, and compartmentalized using Donabedian’s 
framework.  The barrier model in Figure 7 on the following page illustrates this association among 
and between the barriers, as well as the resulting outcomes caused by barriers that are encountered.  
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Identifying the Barriers in the Study  
 
Availability 
 This barrier was categorized as a structure element and described as an external barrier, 
since it related to treatment non-admission caused by filled capacity of the program.  A potential 
availability barrier was identified in the study by non-admissions categorized as “Program Full.” 
Affordability 
 This barrier was categorized as a structure element and also described as an external barrier, 
since access to care may be disallowed by lack of insurance.  A potential affordability barrier was 
identified in the study through the insurance status of clients.   
Figure 7. A synthesis of 3 concepts - the barrier model. 
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Accommodation 
 This barrier was described as an external barrier, and categorized as both a structure and a 
process element, since it related to telecommunications, hours of operation, and modifications to 
the system.  The number of phones was a component of the building.  The hours of operation was 
an organizational process that determined the times that clients could be admitted, and was also 
dependent on staffing structure.  Modification to the system was also an organizational process 
implemented by the nursing staffs.  A potential accommodation barrier was identified in the study 
by times of contact, and through informal interviews with Milestone Foundation leadership. 
Accessibility 
 This barrier was categorized as a process element and described as an external barrier.  
Components of this barrier included family care and responsibility, transportation, health issues, 
and incarceration.  A potential accessibility barrier was identified in the study by the non-
admissions categorized as “No Admission/Show/Call back,” “Legal/Medical Appointment,” 
“Medical Clearance/Higher Level of Care,” and by comments on the detoxification inquiry 
screening form. 
Acceptability 
 This barrier was categorized as both a process and outcome element and described as an 
internal barrier.  Final categorization was based on the premise that all aspects of this barrier – 
shame, stigma, and a fear of consequences and treatment difficulties, were in themselves outcomes, 
yet had the potential to impact actions.  A potential acceptability barrier was identified in the study 
by the non-admissions categorized as “Self-Refused,” and by comments on the detoxification 
inquiry screening form. 
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The Milestone Foundation 
The Barrier Model in Action 
 
 The results of the study demonstrate that the Milestone Foundation acute opioid 
detoxification program anticipates and mitigates many of the potential barriers to women.  This is 
accomplished by counteracting deficiencies of specific components in the barrier model with 
strengths from other components in the category, or with linked components in an associated 
category.  
Structure 
  
Availability 
 The data in the study fail to demonstrate an availability barrier to women’s access.  An 
analysis of the percentages of male and female clients who were not admitted due to a “Program 
full” over the 6 months studies yielded an equal percentage of clients (16.7%) that were turned 
away because of a full program capacity.   
 Milestone Foundation’s structural limitations that are present and adversely impact 
availability (staffing, program capacity, and telecommunications) appear to be counteracted by 
positive actions and results relating to the other classified components in the Structure category:  
Affordability and accommodation. 
 As an additional cautionary note, the absence of this barrier may also be due in part to the 
decreased numbers of women who requested treatment during this time period.  Maine and national 
statistics identify that women are increasingly suffering from opioid use disorders.  As the numbers 
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of female clients increase, the limited bed capacity and the ward-like structure of rooms may 
disproportionately affect women. 
Affordability 
 
 Funding from the state/federal block grants and payments provided through the MaineCare 
and Medicare systems ensured that many men and women who could not afford treatment received 
services at Milestone Foundation.  The study identified that most women who requested treatment 
lacked insurance.  Primarily, 78% women who were admitted either had no insurance (42.2%) or 
had MaineCare/Medicare coverage (35.9%).  Most men admitted lacked insurance (58.1%), and 
about 23% were covered by MaineCare/Medicare.  Subsequently, this access barrier appears to be 
mostly eliminated as well.  However, the study cannot determine how many women self-excluded 
from requesting detoxification, with the misperception that they couldn’t afford treatment.  Out-
of-state women who were not under the umbrella of the state/federal block grant, and could not 
obtain $270, the amount required for admission to the Milestone Foundation detoxification 
program, were also at a disadvantage.  The continued political debate over Medicaid expansion 
adds an additional level of uncertainty. 
Accommodation, Part 1 
 Accommodation as it relates to structure – specifically operational staffing and 
telecommunications, appeared to be a barrier to access.  There is anecdotal evidence of program 
vacancies and concurrent requests for detoxification, yet insufficient staffing to admit clients.  
Since 92% of all requests for admission were received by phone, the telecommunication structure 
is vital.   Two telephone lines may become insufficient to meet demand as requests for admission 
increase, and more staff may be needed to assist clients who call.  Nevertheless, this structural 
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barrier to access appeared to be overcome by the positive aspects of accommodation that were 
identified in the process category. 
Process 
 
Accommodation, Part 2 
 There are several accommodation barriers in the process, however the executive and 
nursing staff at Milestone Foundation have eliminated others by performing modifications to the 
system.  Each detoxification inquiry screening form takes approximately 10 to 15 minutes to 
complete.  The admission procedure is generally performed by the admitting nurse, and the entire 
process may take up to 3 hours to complete.  Admission occurs between 8am and 8:30pm, so the 
number of admissions that can occur are limited.   The limited hours of operation increase the 
potential for a delay in admission, thereby increasing the risk that women will reconsider a decision 
to enter the program.  Discharges may occur at any hour of the day or night (L. Wert, personal 
communication, April 12, 2016).  Over half of the women who requested treatment in the study 
did so between 8am and noon.  Subsequently, women may be less likely than men to call when a 
bed is available, which places them at a disadvantage. 
 While staying within their scope and levels of practice, nursing professionals at Milestone 
Foundation will routinely modify their duties in order to assist other nursing staffs:  The Director 
of Nursing or the charge nurse will often perform screenings or help to admit clients.  When 
possible, changes to men’s room placements are performed if there is a potential to fill a room 
with women.   
 Another modification to the system was recently implemented to mitigate availability 
access barriers for a specific vulnerable population such as pregnant women who suffer from 
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opioid use disorders.  In this new process, if the woman cannot be admitted due to full capacity or 
a lack of female beds, the staffs obtain call-back information, and will attempt to contact the client 
when a bed becomes available.   
Accessibility 
 This barrier encompasses many challenging areas that are outside of the client’s control, 
yet could impact admission.  The No Admission/Show/Call back, Legal/Medical Appointment, 
and Medical Clearance/Higher Level of Care categories were defined as pertaining to the 
accessibility barrier.  No shows/call backs resulted in non-admission for 6 out of 10 clients.   
Subsequently, a review of these non-admission categories demonstrated that this barrier had the 
greatest effect on admission.  When compared to men, women had a slightly higher percentage of 
non-admission, with 71.2% of women and 67.9% of men denied admission due to no show, health, 
legal, or transportation issues.  Indeed, family care and responsibilities may be the reason that the 
study identified more female requests for detoxification on Fridays.  The rationale behind this 
supposition is that other family members would be available to provide childcare or family support 
over the weekend.  The limited hours of admission could also adversely impact transportation, 
since family members or friends may work.  Interestingly, men had a higher percentage of 
comments on the detoxification inquiry screening forms detailing transportation issues. 
 Although men had more medical issues preventing admission, women had more comments 
on the screening forms that described medical issues, with 9% of women who requested treatment 
identifying health problems compared to 4% of men.  In a manner consistent with the literature, 
women also had more comments describing mental health issues.  Admission into the program 
was not impacted by mental health issues, with the exception of behavioral problems, which 
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resulted in non-admission.  In cases where suicidal ideation was present, the client was directed to 
a higher level of care. 
Process and Outcome 
 
Acceptability 
 This is a hidden barrier, and therefore, is potentially the most difficult to identify and assess.  
The percentage male and female clients who refused admission were equal in the study.   Although 
the “No Admit/Show/Call category was utilized in the accessibility category to identify 
transportation and family care issues, it could just as easily be used to demonstrate an outcome of 
shame and stigma, or a fear of consequences or treatment difficulties.  Specific comments 
consistent with this barrier were only noted on female detoxification inquiry screening forms.  
Comments included: 
 Wanted to talk to B[oy] F[riend] and call back to finish inquiry 
 Patient has to go to work and explain to employer 
 Client left after inquiry 
 Mother will drive her from Biddeford 
 
The outcomes on these specific clients were unavailable, given the de-identified information used 
in the study.  Nevertheless, the presence of these comments tends to favor that this barrier is present 
for women, and therefore, also has the potential to impact the process section of the barrier model.   
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The Potential for Health Inequity 
The Insurance Factor 
 
 In 2014, 10.1% of Maine adults lacked health insurance (“SHNAPP,” 2015).  The 2013-
2014 Gallup Poll identified that after implementation of the Affordable Care Act, the percentage 
of Maine’s uninsured individuals decreased from 16.1% in 2013 to 11.1% in 2014 (Witters, 2015). 
Over half, nearly 52% of the 356 individuals in the study who requested opioid detoxification 
services lacked health insurance.  MaineCare and Medicaid accounted for 58% of the health 
insurance coverage for those clients with insurance.  
Substance Use Disorders and Insurance 
 Becker et al. (2008) performed a study on individuals with opiate use disorder, and 
identified that 45% of the population either had no insurance or some form of public insurance, 
such as Medicare or Medicaid.  Individuals without insurance acknowledged the lack of financial 
support as the primary cause of non-treatment (Becker et al., 2008).    
 Women requesting detoxification services at Milestone Foundation were overwhelmingly 
likely to either have no insurance or to have public insurance.  Nearly 78% of the female requests 
for admission in the study met this category.  Over one-third of all women who requested 
detoxification services in the study obtained insurance coverage through MaineCare or Medicare.  
Subsequently, any adverse modifications to public insurance, decreases to services covered, or 
cuts to payments would incur an overwhelming barrier to women’s access of care.  
Medicaid and Public Policy 
 The federal funds available through the Affordable Care Act Medicaid expansion would 
be beneficial to improving access to opioid detoxification services.  As it stands, Maine’s current 
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refusal to receive this distribution prevents the improvements to the detoxification and treatment 
system, and the increased insurance coverage to Maine’s vulnerable populations that it would 
provide.  A recent report estimated that 30% of Maine’s uninsured population suffered from mental 
illness or substance use disorder, and met the income requirements for coverage under the 
expanded Medicaid coverage of the Affordable Care Act (Dey et al., 2016). 
 L.D. 633 is the sixth attempt by members of the Maine Legislature to pass this expansion. 
The bill was submitted by a moderate Republican senator and has bipartisan support (Leary, 2016).  
The expansion legislation recently passed the Senate by a close vote of 18-17, and received an 85-
64 vote in favor in the House.  As with all other attempts at passage, a veto from the Governor is 
expected. 
Centers for Medicare & Medicaid Service (CMS) 
 CMS recently finalized a rule that eliminated a barrier to insurance coverage of substance 
use disorder services.  The mental health and substance use disorder parity rule builds on the 
Mental Health Parity and Addiction Equity Act of 2008, which ensures that these services are 
given equal weight in insurance plans when compared to other medical services.  The rule 
reinforces regulations set forth in the Act by instituting a transparency in benefit information and 
denial (“CMS,” 2016).   Under the new rule, enrollees may request to receive the criteria used by 
insurance plans to determine approval or denial of medical necessity claims.  States who deny 
reimbursement are required to disclose the reasons for denial (“CMS,” 2016).    
Women’s Self-Exclusion 
 
 Self-exclusion, or a failure to initiate the request for detoxification treatment services may 
be the primary limitation to access faced by women, and cannot be identified using the framework 
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set forth in this study.  Causes are numerous, and include most, if not all, of the barrier categories 
in the study.  Justifications may include lack of insurance, inability to contact Milestone 
Foundation, a fear of repercussions or fear of the impact on the family.  Any delays in admission 
may cause women to re-evaluate their decision, and change their mind.  Internalizing behaviors 
such as anxiety or mental health issues may intensify women’s failure to seek treatment. Some 
women may not realize that Milestone Foundation provides services to women, and has funding 
that assists with payment.  Although difficult to assess, the presence of this barrier seems likely by 
the unequal rate of requests for treatment.  If present, it could be overcome using specific strategies. 
Recommendations 
 
 A star (*) denotes that the recommendation may improve female barriers to access.  A 
double star (**) denotes that the recommendation may improve the generation of valid statistical 
data that may be used to improve processes.  Several of these recommendations could be explored 
in future Muskie School of Public Service capstone studies. 
Reinstitute 24 Hour Admissions * 
 
 Initially, the detoxification program utilized 24 hour admissions, and discontinued this 
practice in 2014 when the pharmacy that delivered medications overnight ceased operations (L. 
Wert, personal communication, January 25, 2016).   In January, Maine Medical Center (MMC) 
announced plans to staff the hospital pharmacy on a 24 hour basis (Lawler, 2016).  “The 
Pharmacy” is now open and services are available to patients overnight.  Leadership at Milestone 
Foundation may be able to coordinate an agreement for services with MMC that is mutually 
beneficial to both parties. 
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Ensure Suboxone Availability 
 
 During a portion of the study, the Medical Director’s absence highlighted limitations faced 
by a lack of access to Suboxone.  The back-up provider was not authorized to prescribe, and some 
clients, unable to utilize this treatment regimen, refused admission.  A recent review identified 24 
providers in Portland who are authorized to treat with the medication.  Another back-up provider 
with Medication Assisted Treatment (MAT) certification would ensure Suboxone availability at 
all times.    
Implement Marketing Strategies * 
 
 Revise the Home Page on the Milestone Foundation website to identify women as a client 
population in order to create awareness.  Use a large font for emphasis.  The information 
is currently available in the “About Us” and the “Detoxification” sections on the website 
in 10 point font.  
 Create informational brochures directed towards women and distribute in women’s public 
health locations throughout the state, including Portland Community Health Center, 
Planned Parenthood organizations, and obstetrics/gynecology providers. 
 Continue to utilize current newsworthy events such as public policy debates over Medicaid 
expansions or potential changes to treatment services to speak with the news media.   
 Contact staffs at Maine Public Radio to discuss the potential for informational radio 
programs on addiction and detoxification services in Maine. 
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Revise the Data Inquiry Screening Form ** 
 
 Streamlining the form will simplify it and ensure completion.  Since most clients make 
contact by phone, make this option the default, or remove the section entirely.   
 Frequency of substance use is a primary cause for non-admission.  By placing it higher on 
the assessment list, the screener can quickly identify if detoxification is not required.  
 Use white paper for male screening forms and colored paper for female.  This will allow 
easy identification and sorting for statistical analysis. 
 Ensure that all screening forms are completed, and filled out in a standardized manner.  
Perform regular audits to demonstrate compliance. 
Utilize Other Data on the Data Inquiry Screening Form ** 
 
 Socio-economic markers are collected during screening, and information may be used as a 
metric or statistic.  Data obtained may be of interest to stakeholders, or may allow 
Milestone Foundation to apply for other grant funding. 
Access Available Resources 
 
 Initiate a Practice Transformation.  Maine Quality Counts oversees Maine’s practice 
transformation network, and is available to provide technical and quality information 
assistance in order to improve services and implement best practices.     
 The Maine Quality Counts organization also hosts a “Caring for ME” opioid/heroin online 
resource.  The webpage provides real-time information and free educational webinars 
(“Quality Counts,” 2016). 
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Future - Implement an electronic system for screening and admitting ** 
 
 Acquire and implement a secure electronic system that can be utilized for screening and 
admitting.  The program will populate an electronic version of the form with specific demographic 
and historic information if the client has previously requested treatment.  Some information, like 
gender, birthdate, social security number, and age of alcohol or drug onset will not change.  This 
will increase efficiency while standardizing and simplifying the process.  Data on multiple requests 
for treatment or numerous admissions will be captured easily. 
Future - Improve Telecommunications and Increase Staffing 
 
 Increase telephone access by installing additional lines or queue systems with wait times. 
 Dedicate one employee during the day shift to coordinate telecommunications, and to 
perform the electronic data inquiry screening procedures.  This employee need not be a 
nursing professional, but must be skilled on computer processes, and may be trained to 
perform the screening.  The employee will also be able to collate and extract data from the 
system to help inform decision making and demonstrate successes and challenges. 
 Recruit and employ additional per diem retired nursing professionals.  Utilize these staffs 
on an as needed basis during high volume admission or discharge days to facilitate access 
to treatment.  
Final Thoughts 
 
 Van Etten and Anthony (1999) identified a correlation between the opportunity to use 
substances and the actual substance use.  The research demonstrated that men were more likely 
than women to have opportunities to use substances, however once the opportunity presented, both 
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were equally likely to progress to substance use (Van Etten & Anthony, 1999).  As Maine 
continues to lead the nation in opioid prescription rates, the equal opportunities for substance use 
disorder continue to rise.  Subsequently, men and women are approaching equal rates of opioid 
use disorder.  A failure to approach an equal rate of requests for acute opioid detoxification may 
indicate the continued presence of barriers to access for women.   
 A longitudinal study demonstrated that substance use treatment greatly improves the 
quality of life for women, which is a vital aspect of successful recovery (Pasareanu et al., 2015).  
Improved access to acute opioid detoxification services will promote a health equity between men 
and women, thereby ensuring improved public health for all. 
Conclusion 
 
 Maine’s opioid crisis mirrors a national problem.  The lack of treatment facilities and 
services for opioid use disorder, combined with an increased prevalence of addiction in Maine, 
creates a potential for health inequity between men and women.  Barriers to access will intensify 
that inequity.   
 The barriers to access may be described as internal and external, and categorized using 
Penchansky and Thomas’ (1981) access concepts of availability, affordability, accommodation, 
accessibility, and acceptability.  Donabedian’s (1988) framework of healthcare quality - structure, 
process, and outcome – provides additional classification, thereby further refining our 
understanding of these barriers.  The descriptions and categorizations help to identify associations 
among and between the barriers, which may increase the potential to eliminate them. 
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 Based on the results of the capstone study, the Milestone Foundation performs an excellent 
service to its clients.  The results of the study demonstrate that the Milestone Foundation acute 
opioid detoxification program anticipates and mitigates many of the potential barriers to women.  
Milestone Foundation overcomes its structural limitations by utilizing a comprehensive, yet 
flexible process that can be modified to address specific issues.  This is accomplished by 
counteracting deficiencies of specific components in the barrier model with strengths from other 
components in the category, or with linked components in an associated category.  The system 
appears to mitigate many of the barriers to access that women may encounter.  Barriers that prevent 
women from requesting treatment may still present a problem.  Further revisions may be necessary 
as the prevalence of opioid use disorder in women continue.   
 Combining state and national forces with Medicaid expansion will increase funding and 
strengthen the structure of Maine’s opioid treatment services.  By understanding and eliminating 
women’s barriers to access in acute opioid detoxification services, we will realize the successful 
outcome of public health for all of Maine’s citizens.   
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Appendix B:  Detoxification Inquiry Screening Form 
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Appendix C:  Detoxification Inquiry Screening Form Data 
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8a-12n 12:01-4p 4:01-8p
YES, 
Private
YES, Public NO
M 1/1/2015 Thurs P X X
M 1/5/2015 Mon P X X X
Client must attend 2AA 
meetings prior to admission
M 1/6/2015 Tues P X X
M 1/12/2015 Mon P X X X
M 1/12/2015 Mon P X X X
M 1/15/2015 Thurs P X X X Client Refused Admission
F 1/17/2015 Sat P X X
M 1/17/2015 Sat P X X X
F 1/18/2015 Sun P X X X
M 1/18/2015 Sun P X UNK UNK UNK Behavior Issues
M 1/19/2015 Mon P X X X
F 1/20/2015 Tues P X X
F 1/21/2015 Wed P X X
F 1/21/2015 Wed P X X
M 1/21/2015 Wed P X X
M 1/22/2015 Thurs W X X X
F 1/25/2015 Sun P X UNK UNK UNK UNK
M 1/28/2015 Wed P X X
F 1/29/2015 Thurs P X X
M 1/30/2015 Fri P X X X
M 2/1/2015 Sun P X X
F 2/2/2015 Mon P X X X
M 2/3/2015 Tues P X X X
M 2/3/2015 Tues P X X X
M 2/6/2015 Fri P X X
M 2/6/2015 Fri P X X X
M 2/7/2015 Sat P X (03:50) X X
M 2/8/2015 Sun P X X X
Will call back, requesting 
admission tomorrow
M 2/9/2015 Mon P X X X
F 2/11/2015 Wed P X X
F 2/12/2015 Thurs P X X X
M 2/14/2015 Sat P X X
M 2/14/2015 Sat P X (07:36) X
M 2/15/2015 Sun P X X
M 2/16/2015 Mon P X X X
F 2/18/2015 Wed P X X
M 2/18/2015 Wed UNK UNK UNK UNK X
M 2/18/2015 Wed W UNK UNK UNK X
F 2/19/2015 Thurs P UNK UNK UNK X
M 2/19/2015 Thurs P X X X
F 2/20/2015 Fri P X (21:20) X Coming in around 10a 2/21/15
M 2/20/2015 Fri P UNK UNK UNK X Will call in AM
M 2/20/2015 Fri P X X X
UNK 2/20/2015 Fri P X UNK UNK UNK
F 2/22/2015 Sun P X X X Referred to St Mary's MRC
M 2/22/2015 Sun P X X X
No Admission Nurse, to call 
back
M 2/22/2015 Sun P X (06:40) UNK UNK UNK UNK To call back at 8a
M 2/22/2015 Sun P X X X
M 2/23/2015 Mon P X X X
M 2/24/2015 Tues P X X
F 2/27/2015 Fri P X X
Do not admit with current 
client
M 2/27/2015 Fri P X X
Detox not required - one time 
use
M 2/27/2015 Fri P X X X
Do not admit with current 
client 
F 2/28/2015 Sat UNK X X X Referred to Mercy ED
M 6/2/2015 Tues P X X X
M 6/2/2015 Tues P X X X
F 6/3/2015 Wed P X X Will call back in a few hours
M 6/4/2015 Thurs P X X X
M 6/7/2015 Sun P X X
Do not admit with current 
client 
M 6/7/2015 Sun P X
Homeless Comments
Gender 
(M/F)
Date
Day of 
Week
Mode of Contact 
(Phone/ Walkin)
Time of Inquiry Health Insurance
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8a-12n 12:01-4p 4:01-8p
YES, 
Private
YES, Public NO
M 6/11/2015 Thurs P X X
Will call tomorrow to see if an 
empty bed
M 6/11/2015 Thurs P X X X
M 6/11/2015 Thurs P X X
F 6/13/2015 Sat P X X X
M 6/15/2015 Mon P X X No Show
F 6/16/2015 Tues P UNK UNK UNK X Referred to Mercy Recovery
F 6/16/2015 Tues P X X
M 6/16/2015 Tues P X (07:45) X
M 6/17/2015 Wed P X X
M 6/17/2015 Wed P X X X
F 6/19/2015 Fri P X X
F 6/20/2015 Sat P UNK UNK UNK X Arriving at 2pm
M 6/21/2015 Sun P X X At ED 2 nights ago for detox
M 6/21/2015 Sun P UNK UNK UNK X Will call back with ride
M 6/21/2015 Sun P X (07:30) X
M 6/21/2015 Sun P X X
F 6/22/2015 Mon P X X Currently at St Mary's Crisis
M 6/22/2015 Mon P X X
M 6/22/2015 Mon P X X X
M 6/23/2015 Tues P X X
45 min drive, will call 
tomorrow
F 6/26/2015 Fri P X X
M 6/26/2015 Fri P X X Will call back  
M 6/26/2015 Fri P X (07:30) X X
M 6/29/2015 Mon P X X X
Has not used in 7 days, detox 
not needed
M 6/29/2015 Mon P X X X Will call tomorrow
M 6/29/2015 Mon P X X
Will call tomorrow, recent 
overdose
M 6/29/2015 Mon P X X
M 6/30/2015 Tues P X X X
F 7/1/2015 Wed P UNK UNK UNK X No Suboxone, will call back
M 7/1/2015 Wed P X UNK UNK UNK
Client was told no Suboxone. 
Wants to think about it and 
may call back
M 7/1/2015 Wed P X X Will call back with ride
F 7/2/2015 Thurs P X UNK UNK UNK
Knows no Suboxone, will call 
back within the hour
F 7/2/2015 Thurs P X X
Will call back to check on bed 
availability later
F 7/3/2015 Fri P X X Has been told no Suboxone
F 7/3/2015 Fri P X (07:40) X Knows no Suboxone
F 7/3/2015 Fri P X (07:15) UNK UNK UNK X
Told about no Suboxone, 
wants to think about it, may 
call back
M 7/3/2015 Fri P X X
Suboxone not available, 
refused admission
M 7/3/2015 Fri P UNK UNK UNK X Will call back
M 7/3/2015 Fri P X X
Will call back to see if we 
have a bed
F 7/9/2015 Thurs P X X
M 7/9/2015 Thurs P X X X
M 7/9/2015 Thurs P X X
F 7/10/2015 Fri P UNK UNK UNK X
F 7/11/2015 Sat P X (22:00) X
Client has blood in GI, 
Referred to local ED for med 
clearance, will call in AM
F 7/11/2015 Sat W X X X Client left after inquiry
F 7/11/2015 Sat P X X
Will call back when gets a ride 
(program full when called 
back)
M 7/11/2015 Sat P X X
F 7/12/2015 Sun P UNK UNK UNK X X
F 7/13/2015 Mon P UNK UNK UNK X
F 7/14/2015 Tues P X X X NH Medicaid
F 7/14/2015 Tues P X X
Patient has to go to work and 
explain to employer
Homeless Comments
Gender 
(M/F)
Date
Day of 
Week
Mode of Contact 
(Phone/ Walkin)
Time of Inquiry Health Insurance
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8a-12n 12:01-4p 4:01-8p
YES, 
Private
YES, Public NO
F 7/14/2015 Tues P X X
Wants to come in later this 
afternoon
M 7/14/2015 Tues P X X X Client refused admission
F 7/15/2015 Wed P X X Looking for a ride
F 7/15/2015 Wed P X X
M 7/15/2015 Wed P X X X
M 7/16/2015 Thurs P X X X
Client needs to go to ED for 
blood in vomit
M 7/16/2015 Thurs P X X X
Client needs to go to ED for 
blood in vomit
F 7/17/2015 Fri UNK UNK UNK UNK X
F 7/18/2015 Sat P X X
M 7/19/2015 Sun P X X
M 7/20/2015 Mon P X X X No use for 9 days
M 7/22/2015 Wed P X X X
F 7/23/2015 Thurs P X (07:30) X
M 7/23/2015 Thurs P X X
M 7/23/2015 Thurs P X X X
M 7/23/2015 Thurs P X X
F 7/24/2015 Fri P X X Wants to come in August 1st
M 7/24/2015 Fri P X (21:15) X X
M 7/27/2015 Mon P X X X
Client looking to come in 
tomorrow. Will call then.
M 7/27/2015 Mon P X X X
Client needs to rearrange 
appointments prior to 
admission
M 7/27/2015 Mon P X X
M 7/27/2015 Mon W X X
F 7/28/2015 Tues P X X
M 7/28/2015 Tues P X X
M 7/29/2015 Wed P/W X X
M 7/29/2015 Wed P UNK UNK UNK X
F 7/30/2015 Thurs UNK UNK UNK UNK UNK UNK UNK X
Client will call in AM to finish 
inquiry
M 7/30/2015 Thurs W X X
Overdosed last night and woke 
up in ambulance
M 7/30/2015 Thurs P X (04:00) X Will call back at 8am
M 7/30/2015 Thurs UNK UNK UNK UNK X
F 7/31/2015 Fri P X (04:15) UNK UNK UNK
Wanted to talk to BF and call 
back to finish inquiry
F 7/31/2015 Fri P X X
M 7/31/2015 Fri P X X
F 2/1/2016 Mon P X X X
Lt side pain #5-6, Has 
employer
M 2/1/2016 Mon W X X X
M 2/2/2016 Tues W UNK UNK UNK X X
F 2/3/2016 Wed UNK UNK UNK UNK X X No ID from Maine
F 2/3/2016 Wed P UNK UNK UNK X
M 2/3/2016 Wed P X X X
Out of state resident, been in 
Maine 4 months
M 2/3/2016 Wed P X (05:00) X
Will call back at 8am for adm, 
left 2 days ago AMA to get 
nicotine patches
M 2/3/2016 Wed P X X X Will maybe call tomorrow AM
F 2/5/2016 Fri P X X
M 2/5/2016 Fri P X X X
Out of state resident, needs to 
be told no suboxone
M 2/5/2016 Fri P X (22:00) X X
M 2/7/2016 Sun P X X
Has to work Monday, out of 
state resident, visiting friends
M 2/7/2016 Sun P X X
Medical clearance needed GI 
Bleed
M 2/7/2016 Sun P X X
M 2/8/2016 Mon P X (07:45) X
Told to bring a piece of mail 
with address (confirmation of 
Maine residency)
F 2/9/2016 Tues P X X
Do not admit with current 
client
Homeless Comments
Gender 
(M/F)
Date
Day of 
Week
Mode of Contact 
(Phone/ Walkin)
Time of Inquiry Health Insurance
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8a-12n 12:01-4p 4:01-8p
YES, 
Private
YES, Public NO
M 2/9/2016 Tues P X X
Dr note clearing for detox, No 
show
F 2/10/2016We+C58:C69d P X X X
OD last night, friend used 
Narcan, No show
M 2/10/2016 Wed P X X
1 1/2 hours away, trying to 
find a ride
M 2/10/2016 Wed P X X X
Do not admit with current 
client
F 2/11/2016 Thurs P X X Needs to bring in $270
F 2/11/2016 Thurs P X X X
F 2/12/2016 Fri UNK UNK UNK UNK X Needs a higher level of care
F 2/14/2016 Sun P X X X
Mother will drive her from 
Biddeford
F 2/16/2016 Tues P X X X
Has been told she needs to 
bring in $270, will call when 
ready
M 2/16/2016 Tues P UNK UNK UNK X Will call after 8am
F 2/17/2016 Wed P X X X
Sent to Mercy ED for 
assessment of possible 
cellulitis left arm
M 2/18/2016 Thurs P X X Needs to find ride
M 2/18/2016 Thurs P X X
Wants to come in with wife.  
XXXX told him we do not allow 
couples together
M 2/18/2016 Thurs P X X
M 2/19/2016 Fri P X X Called again 2/21 at 11:00
M 2/19/2016 Fri P X X X No show
M 2/20/2016 Sat P X X
Full, 2 hours away, told to call 
back later, called again 2/21 
at 18:00
M 2/20/2016 Sat P X X Will call back in AM
F 2/21/2016 Sun P UNK UNK UNK X
Going to ED for med 
clearance, r/o GI Bleed
M 2/21/2016 Sun P X X
M 2/22/2016 Mon P UNK UNK UNK UNK UNK UNK Will call back Wed after appt
M 2/22/2016 Mon P UNK UNK UNK X
M 2/22/2016 Mon P UNK UNK UNK X
M 2/24/2016 Wed P UNK UNK UNK X
M 2/24/2016 Wed UNK UNK UNK UNK X
M 2/25/2016 Thurs P X (07:15) X
4 hours away, will call back 
when ride is situated
M 2/26/2016 Fri P X X
Client looking to come in on 
the 27th 
F 2/27/2016 Sat P X X
DV survivor, call back to see if 
admit today
M 2/28/2016 Sun P X X Needs clearance #6 Chest Pain
M 2/28/2016 Sun P X X
F 2/29/2016 Mon P X X
M 2/29/2016 Mon P X X
Needs a ride, will check 
tomorrow
M 2/29/2016 Mon P X X
M 2/29/2016 Mon P X X
F UNK UNK P UNK UNK UNK X
F UNK UNK P UNK UNK UNK X
Gender 
(M/F)
Date
Day of 
Week
Mode of Contact 
(Phone/ Walkin)
Time of Inquiry Health Insurance
Homeless Comments
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Month-Year Gender Resolution Substance Insurance Repeat Client
Jan-15 female legal or medical apt that would prevent completion Opiate No insurance yes
Jan-15 Female No Admit/Show/Call back Opiate No insurance no
Jan-15 Female No Admit/Show/Call back Opiate No insurance no
Jan-15 female No Admit/Show/Call back Opiate No insurance yes
Jan-15 Female Program Full Opiate No insurance no
Jan-15 Female No Admit/Show/Call back Opiate Yes (Mecare/medicare) yes
Jan-15 female Ct admitted to Detox Opiate Yes (private insurance) no
Jan-15 female Ct admitted to Detox Opiate Yes (private insurance) yes
Jan-15 Male Ct not in need of medical detox Opiate - no
Jan-15 Male needs medical/PHY clearance Opiate - no
Jan-15 Male behavoir issues Opiate No insurance yes
Jan-15 Male Ct admitted to Detox Opiate No insurance no
Jan-15 Male Ct admitted to Detox Opiate No insurance no
Jan-15 Male Ct admitted to Detox Opiate No insurance yes
Jan-15 Male Ct self refused detox Opiate No insurance no
Jan-15 Male Ct self refused detox Opiate No insurance yes
Jan-15 Male needs medical/PHY clearance Opiate No insurance no
Jan-15 Male No Admit/Show/Call back Opiate No insurance no
Jan-15 Male No Admit/Show/Call back Opiate No insurance no
Jan-15 Male No Admit/Show/Call back Opiate No insurance no
Jan-15 Male No Admit/Show/Call back Opiate No insurance yes
Jan-15 Male Program Full Opiate No insurance no
Jan-15 Male Program Full Opiate No insurance no
Jan-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jan-15 Male Ct admitted to Detox Opiate Yes (private insurance) yes
Feb-15 Female Ct admitted to Detox Opiate No insurance no
Feb-15 Female Ct admitted to Detox Opiate No insurance no
Feb-15 Female No Admit/Show/Call back Opiate No insurance no
Feb-15 Female Program Full Opiate No insurance no
Feb-15 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Feb-15 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Feb-15 Female ct can not be admitted with current detox client Opiate Yes (Mecare/medicare) no
Feb-15 Female No Admit/Show/Call back Opiate Yes (private insurance) yes
Feb-15 Male higher level of care Opiate - -
Feb-15 Male Program Full Opiate - -
Feb-15 Male Ct admitted to Detox Opiate No insurance no
Feb-15 Male Ct admitted to Detox Opiate No insurance no
Feb-15 male Ct admitted to Detox Opiate No insurance no
Feb-15 male Ct admitted to Detox Opiate No insurance no
Feb-15 Male Ct admitted to Detox Opiate No insurance yes
Feb-15 Male Ct admitted to Detox Opiate No insurance yes
Feb-15 Male Ct admitted to Detox Opiate No insurance yes
Feb-15 Male Ct not in need of medical detox Opiate No insurance yes
Feb-15 Male legal or medical apt that would prevent completion Opiate No insurance yes
Feb-15 Male No Admit/Show/Call back Opiate No insurance no
Feb-15 Male No Admit/Show/Call back Opiate No insurance no
Feb-15 Male No Admit/Show/Call back Opiate No insurance yes
Feb-15 Male No Admit/Show/Call back Opiate No insurance yes
Feb-15 Male No Admit/Show/Call back Opiate No insurance yes
Feb-15 male Program Full Opiate No insurance no
Feb-15 Male Program Full Opiate No insurance no
Feb-15 Male Program Full Opiate No insurance no
Feb-15 Male Program Full Opiate No insurance yes
Feb-15 Male Program Full Opiate No insurance yes
Feb-15 male ct can not be admitted with current detox client Opiate Yes (Mecare/medicare) no
Feb-15 Male Ct not in need of medical detox Opiate Yes (Mecare/medicare) yes
Feb-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Feb-15 Male Program Full Opiate Yes (Mecare/medicare) yes
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Month-Year Gender Resolution Substance Insurance Repeat Client
Feb-15 Male Ct admitted to Detox Opiate Yes (private insurance) yes
Feb-15 Male ct can not be admitted with current detox client Opiate Yes (private insurance) no
Feb-15 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Feb-15 male Program Full Opiate Yes (private insurance) no
Feb-15 Male Program Full Opiate Yes (private insurance) no
Feb-15 Female Ct not in need of medical detox Opiate - yes
Feb-15 Female No Admit/Show/Call back Opiate No insurance yes
Feb-15 Male Ct admitted to Detox Opiate No insurance yes
Jun-15 Female No Admit/Show/Call back Opiate - no
Jun-15 Female Ct admitted to Detox Opiate No insurance no
Jun-15 Female Ct admitted to Detox Opiate No insurance no
Jun-15 Female Ct admitted to Detox Opiate No insurance no
Jun-15 Female No Admit/Show/Call back Opiate No insurance no
Jun-15 Female No Admit/Show/Call back Opiate No insurance no
Jun-15 Female No Admit/Show/Call back Opiate No insurance no
Jun-15 Female No Admit/Show/Call back Opiate No insurance yes
Jun-15 Female Program Full Opiate No insurance no
Jun-15 Female Program Full Opiate No insurance no
Jun-15 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jun-15 Female No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jun-15 Female Program Full Opiate Yes (Mecare/medicare) no
Jun-15 Female Ct admitted to Detox Opiate Yes (private insurance) no
Jun-15 Female Ct admitted to Detox Opiate Yes (private insurance) no
Jun-15 Female Ct admitted to Detox Opiate Yes (private insurance) yes
Jun-15 Female No Admit/Show/Call back Opiate Yes (private insurance) no
Jun-15 Female No Admit/Show/Call back Opiate Yes (private insurance) no
Jun-15 Female No Admit/Show/Call back Opiate Yes (private insurance) no
Jun-15 Male Ct not in need of medical detox Opiate - no
Jun-15 Male Inquiry Not Complete Opiate - yes
Jun-15 Male Ct admitted to Detox Opiate No insurance no
Jun-15 Male Ct admitted to Detox Opiate No insurance no
Jun-15 Male Ct admitted to Detox Opiate No insurance yes
Jun-15 Male Ct admitted to Detox Opiate No insurance yes
Jun-15 Male Ct admitted to Detox Opiate No insurance yes
Jun-15 Male ct can not be admitted with current detox client Opiate No insurance yes
Jun-15 Male Ct self refused detox Opiate No insurance yes
Jun-15 Male higher level of care Opiate No insurance no
Jun-15 Male higher level of care Opiate No insurance yes
Jun-15 Male No Admit/Show/Call back Opiate No insurance no
Jun-15 Male No Admit/Show/Call back Opiate No insurance no
Jun-15 Male No Admit/Show/Call back Opiate No insurance no
Jun-15 Male No Admit/Show/Call back Opiate No insurance yes
Jun-15 Male No Admit/Show/Call back Opiate No insurance yes
Jun-15 Male No Admit/Show/Call back Opiate No insurance yes
Jun-15 Male No Admit/Show/Call back Opiate No insurance yes
Jun-15 Male No Admit/Show/Call back Opiate No insurance yes
Jun-15 Male No Admit/Show/Call back Opiate No insurance yes
Jun-15 Male No Admit/Show/Call back Opiate No insurance yes
Jun-15 Male No Admit/Show/Call back Opiate No insurance yes
Jun-15 Male Program Full Opiate No insurance no
Jun-15 Male Program Full Opiate No insurance no
Jun-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jun-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jun-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jun-15 Male Ct not in need of medical detox Opiate Yes (Mecare/medicare) no
Jun-15 Male Ct self refused detox Opiate Yes (Mecare/medicare) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) yes
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Month-Year Gender Resolution Substance Insurance Repeat Client
Jun-15 Male Program Full Opiate Yes (Mecare/medicare) yes
Jun-15 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jun-15 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jun-15 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jun-15 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jun-15 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jun-15 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jun-15 Male Ct admitted to Detox Opiate Yes (private insurance) yes
Jun-15 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Jun-15 Male No Admit/Show/Call back Opiate Yes (private insurance) yes
Jul-15 Female No Admit/Show/Call back Opiate - no
Jul-15 Female No Admit/Show/Call back Opiate - no
Jul-15 Female No Admit/Show/Call back Opiate - no
Jul-15 Female No Admit/Show/Call back Opiate - yes
Jul-15 Female behavoir issues Opiate No insurance yes
Jul-15 Female Ct admitted to Detox Opiate No insurance no
Jul-15 Female Ct self refused detox Opiate No insurance no
Jul-15 Female Ct self refused detox Opiate No insurance no
Jul-15 Female legal or medical apt that would prevent completion Opiate No insurance no
Jul-15 Female No Admit/Show/Call back Opiate No insurance no
Jul-15 Female No Admit/Show/Call back Opiate No insurance no
Jul-15 Female No Admit/Show/Call back Opiate No insurance no
Jul-15 Female No Admit/Show/Call back Opiate No insurance yes
Jul-15 Female No Admit/Show/Call back Opiate No insurance yes
Jul-15 Female Program Full Opiate No insurance no
Jul-15 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jul-15 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jul-15 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jul-15 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jul-15 Female Ct self refused detox Opiate Yes (Mecare/medicare) no
Jul-15 Female No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jul-15 Female No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jul-15 Female Ct admitted to Detox Opiate Yes (private insurance) no
Jul-15 Female Ct admitted to Detox Opiate Yes (private insurance) yes
Jul-15 Female higher level of care Opiate Yes (private insurance) yes
Jul-15 Female needs medical/PHY clearance Opiate Yes (private insurance) no
Jul-15 Female No Admit/Show/Call back Opiate Yes (private insurance) no
Jul-15 Female No Admit/Show/Call back Opiate Yes (private insurance) no
Jul-15 Female No Admit/Show/Call back Opiate Yes (private insurance) yes
Jul-15 Female Program Full Opiate Yes (private insurance) yes
Jul-15 Male Ct admitted to Detox Opiate - no
Jul-15 Male No Admit/Show/Call back Opiate - yes
Jul-15 Male Ct admitted to Detox Opiate No insurance no
Jul-15 Male Ct admitted to Detox Opiate No insurance no
Jul-15 Male Ct admitted to Detox Opiate No insurance no
Jul-15 Male Ct admitted to Detox Opiate No insurance yes
Jul-15 Male Ct admitted to Detox Opiate No insurance yes
Jul-15 Male Ct admitted to Detox Opiate No insurance yes
Jul-15 Male Ct admitted to Detox Opiate No insurance yes
Jul-15 Male Ct not in need of medical detox Opiate No insurance no
Jul-15 Male needs medical/PHY clearance Opiate No insurance no
Jul-15 Male No Admit/Show/Call back Opiate No insurance no
Jul-15 Male No Admit/Show/Call back Opiate No insurance yes
Jul-15 Male Program Full Opiate No insurance no
Jul-15 Male Program Full Opiate No insurance no
Jul-15 Male Program Full Opiate No insurance no
Jul-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jul-15 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jul-15 Male Ct self refused detox Opiate Yes (Mecare/medicare) no
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Month-Year Gender Resolution Substance Insurance Repeat Client
Jul-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) yes
Jul-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) yes
Jul-15 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) yes
Jul-15 Male Program Full Opiate Yes (Mecare/medicare) no
Jul-15 Male Program Full Opiate Yes (Mecare/medicare) yes
Jul-15 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jul-15 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jul-15 Male Ct admitted to Detox Opiate Yes (private insurance) yes
Jul-15 Male Ct self refused detox Opiate Yes (private insurance) no
Jul-15 Male legal or medical apt that would prevent completion Opiate Yes (private insurance) yes
Jul-15 Male No Admit/Show/Call back Opiate Yes (private insurance) yes
Jul-15 Male Program Full Opiate Yes (private insurance) yes
Jan-16 Female Ct admitted to Detox Opiate No insurance no
Jan-16 Female Ct admitted to Detox Opiate No insurance no
Jan-16 Female Ct admitted to Detox Opiate No insurance no
Jan-16 Female higher level of care Opiate No insurance no
Jan-16 Female No Admit/Show/Call back Opiate No insurance yes
Jan-16 Female Program Full Opiate No insurance yes
Jan-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) -
Jan-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jan-16 Female Inquiry Not Complete Opiate Yes (Mecare/medicare) no
Jan-16 Female No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jan-16 Female No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jan-16 Female Program Full Opiate Yes (Mecare/medicare) no
Jan-16 Female Program Full Opiate Yes (Mecare/medicare) no
Jan-16 Female Program Full Opiate Yes (private insurance) yes
Jan-16 Male Ct not in need of medical detox Opiate - no
Jan-16 Male Ct not in need of medical detox Opiate - no
Jan-16 Male Program Full Opiate - yes
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance no
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate No insurance yes
Jan-16 Male Ct not in need of medical detox Opiate No insurance no
Jan-16 Male Ct self refused detox Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
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Month-Year Gender Resolution Substance Insurance Repeat Client
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance no
Jan-16 Male No Admit/Show/Call back Opiate No insurance yes
Jan-16 Male No Admit/Show/Call back Opiate No insurance yes
Jan-16 Male No Admit/Show/Call back Opiate No insurance yes
Jan-16 Male No Admit/Show/Call back Opiate No insurance yes
Jan-16 Male Program Full Opiate No insurance no
Jan-16 Male Program Full Opiate No insurance yes
Jan-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Jan-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jan-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jan-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Jan-16 Male Ct not in need of medical detox Opiate Yes (Mecare/medicare) yes
Jan-16 Male needs medical/PHY clearance Opiate Yes (Mecare/medicare) no
Jan-16 Male needs medical/PHY clearance Opiate Yes (Mecare/medicare) yes
Jan-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jan-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jan-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jan-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jan-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Jan-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) yes
Jan-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) yes
Jan-16 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jan-16 Male Ct admitted to Detox Opiate Yes (private insurance) no
Jan-16 Male Ct admitted to Detox Opiate Yes (private insurance) yes
Jan-16 Male Ct admitted to Detox Opiate Yes (private insurance) yes
Jan-16 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Jan-16 Male No Admit/Show/Call back Opiate Yes (private insurance) yes
Jan-16 Male No Admit/Show/Call back Opiate Yes (private insurance) yes
Jan-16 Male No Admit/Show/Call back Opiate Yes (private insurance) yes
Jan-16 Male Program Full Opiate Yes (private insurance) no
Jan-16 Male Program Full Opiate Yes (private insurance) no
Feb-16 Female No Admit/Show/Call back Opiate - no
Feb-16 Female No Admit/Show/Call back Opiate NH Wellsense no
Feb-16 Female Ct admitted to Detox Opiate No insurance no
Feb-16 Female Ct admitted to Detox Opiate No insurance no
Feb-16 Female Ct admitted to Detox Opiate No insurance no
Feb-16 Female Ct admitted to Detox Opiate No insurance yes
Feb-16 Female Ct admitted to Detox Opiate No insurance yes
Feb-16 Female Ct admitted to Detox Opiate No insurance yes
Feb-16 Female ct can not be admitted with current detox client Opiate No insurance no
Feb-16 Female No Admit/Show/Call back Opiate No insurance no
Feb-16 Female No Admit/Show/Call back Opiate No insurance no
Feb-16 Female No Admit/Show/Call back Opiate No insurance no
Feb-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Feb-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Feb-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Feb-16 Female Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Feb-16 Female higher level of care Opiate Yes (Mecare/medicare) no
Feb-16 Female No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Feb-16 Female No Admit/Show/Call back Opiate Yes (private insurance) no
Feb-16 Female No Admit/Show/Call back Opiate Yes (private insurance) yes
Feb-16 Male Ct admitted to Detox Opiate - -
Feb-16 Male Ct admitted to Detox Opiate - yes
Feb-16 Male Inquiry Not Complete Opiate - yes
Feb-16 Male legal or medical apt that would prevent completion Opiate - no
Feb-16 Male No Admit/Show/Call back Opiate - no
Feb-16 Male No Admit/Show/Call back Opiate - yes
Feb-16 Male Ct admitted to Detox Opiate No insurance no
Feb-16 Male Ct admitted to Detox Opiate No insurance no
Feb-16 Male Ct admitted to Detox Opiate No insurance no
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Feb-16 Male Ct admitted to Detox Opiate No insurance no
Feb-16 Male Ct admitted to Detox Opiate No insurance no
Feb-16 Male Ct admitted to Detox Opiate No insurance no
Feb-16 Male Ct admitted to Detox Opiate No insurance no
Feb-16 Male Ct admitted to Detox Opiate No insurance no
Feb-16 Male Ct admitted to Detox Opiate No insurance no
Feb-16 Male Ct admitted to Detox Opiate No insurance yes
Feb-16 Male Ct admitted to Detox Opiate No insurance yes
Feb-16 Male Ct admitted to Detox Opiate No insurance yes
Feb-16 Male needs medical/PHY clearance Opiate No insurance no
Feb-16 Male needs medical/PHY clearance Opiate No insurance no
Feb-16 Male needs medical/PHY clearance Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance no
Feb-16 Male No Admit/Show/Call back Opiate No insurance yes
Feb-16 Male No Admit/Show/Call back Opiate No insurance yes
Feb-16 Male Program Full Opiate No insurance yes
Feb-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Feb-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Feb-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Feb-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) no
Feb-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Feb-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Feb-16 Male Ct admitted to Detox Opiate Yes (Mecare/medicare) yes
Feb-16 Male higher level of care Opiate Yes (Mecare/medicare) no
Feb-16 Male needs medical/PHY clearance Opiate Yes (Mecare/medicare) yes
Feb-16 Male needs medical/PHY clearance Opiate Yes (Mecare/medicare) yes
Feb-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Feb-16 Male No Admit/Show/Call back Opiate Yes (Mecare/medicare) no
Feb-16 Male Ct admitted to Detox Opiate Yes (private insurance) no
Feb-16 Male Ct admitted to Detox Opiate Yes (private insurance) no
Feb-16 Male ct can not be admitted with current detox client Opiate Yes (private insurance) yes
Feb-16 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Feb-16 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Feb-16 Male No Admit/Show/Call back Opiate Yes (private insurance) no
Feb-16 Male No Admit/Show/Call back Opiate Yes (private insurance) yes
